Search criteria | ||||
Burden of Hospitalizations and Outpatient Visits Associated With Moderate and Severe Acute Graft-Versus-Host Disease in Finland and Sweden: A Real-World Data Analysis | ||||
Lorenzo Sabatelli, PhD,1 Mikko Keränen, MD, PhD,2 Elisabet Viayna, PhD,3 Montserrat Roset, BSc Stats,3 Nuria Lara, MD, MSc,3 Daniel Thunström, MSc Pharm,1 Minja Pfeiffer, PhD,1 Malin Nicklasson, MSc Pharm,4 Maija Itälä-Remes, MD, PhD5 | ||||
"1Incyte Biosciences International Sàrl, Morges, Switzerland; 2Helsinki University Hospital, Helsinki, Finland; 3IQVIA Real World Solutions, Barcelona, Spain; 4Department of Hematology and Coagulation, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; 5Turku University Hospital, Turku, Finland " | ||||
Supportive Care in Cancer |
||||
, Article | ||||
, Finland, Spain, Sweden, Switzerland | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Transplant | 2022 | English | , Clinical setting: hospital, Observational study, Population Based Study | |
Cost analysis of sequencing new agents for the treatment of chronic lymphocytic leukemia from the perspective of the Brazilian supplementary health system | ||||
Leandro Brust (1), Celso Arrais (2), Fabiano Pombo (3), Diego Kashiura (4), Pedro Vitor Pereira Lima (4), Ana Travassos (5), Rafael Silva (5), Straus Tanaka (5) | ||||
1: Dasa, Rio Grande do Sul, Brasil; 2: Universidade Federal de São Paulo, São Paulo, SP, Brasil; 3: Américas Centro de Oncologia Integrado, Rio de Janeiro, RJ, Brasil; 4: IQVIA Real World Insights Brazil, São Paulo, SP, Brasil; 5: AbbVie Brasil, São Paulo, SP, Brasil. | ||||
J Bras Econ Saúde 2022;14(1):80-8 |
||||
, Article | ||||
, Brazil | ||||
Abstract: https://jbes.com.br/wp-content/uploads/2022/05/JBES_141_80-88.pdf | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Hematology | 2022 | Portuguese | , Cost effectiveness | |
Direct costs associated with lupus nephritis management in the Private Healthcare System in Brazil: an expert panel perspective | ||||
Danielle O. Silva (1), Nathalie David (1), Bruce Y. Kano (2), Diego Kashiura (2), Odirlei A. Monticielo (3), André Hayata (4), Mariana R. Gazzotti (1), Graziela Bernardino (1) | ||||
1: GSK, Rio de Janeiro, RJ, Brasil; 2: IQVIA Real World Insights, São Paulo, SP, Brazil; 3: Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil; 4: Centro de Reumatologia Avançada, São Paulo, SP, Brazil | ||||
J Bras Econ Saúde 2022;14(3):232-46 |
||||
, Article | ||||
, Brazil | ||||
Abstract: https://jbes.com.br/wp-content/uploads/2022/12/JBES_143-p232-246.pdf | ||||
Condition | Year | Language | Analysis type | |
, Dermatology, Health economics | 2022 | English | , Cost analysis | |
Budget impact analysis of Jivi® (damoctocog alfa pegol, BAY 94-9027) in severe Hemophilia A in Japan | ||||
Teruhisa Fujii 1, Yuko Kidoguchi 2, Noriko Takahashi 2, Eric Yu 3, Dilinuer Ainiwaer 3, Aidan Byrne 4 (rwesheorj 3) | ||||
1) Division of Blood Transfusion, Hiroshima University Hospital, Hiroshima, Japan 2) Market Access, Bayer Yakuhin, Ltd., Tokyo, Japan 3) IQVIA Solutions Japan K.K., Tokyo, Japan 4) IQVIA UK, London, UK | ||||
Journal of Medical Economics |
||||
, Article | ||||
, Japan | ||||
Abstract: https://www.tandfonline.com/doi/full/10.1080/13696998.2021.1875788 | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2021 | English | , Budget impact | |
High‑Expenditure Disease in the EU‑28: Does Drug Spend Correspond to Clinical and Economic Burden in Oncology, Autoimmune Disease and Diabetes? | ||||
Wolfgang Greiner, Keyur Patel, Christina-Jane Crossman-Barnes, Troels Vingtoft Rye-Andersen, Christian Hvid, Tom Vandebrouck | ||||
Department for Health Economics, Bielefeld University, Bielefeld, Germany; IQVIA Ltd, HEOR, London, UK; Novo Nordisk Region Europe Pharmaceuticals A/S, Copenhagen, Denmark; Novo Nordisk Region Europe Pharmaceuticals A/S, Brussels, Belgium | ||||
PharmacoEconomics-Open. 2021 Jan; doi.org/10.1007/s41669-020-00253-4 |
||||
, Article | ||||
, Europe | ||||
Abstract: https://link.springer.com/epdf/10.1007/s41669-020-00253-4?sharing_token=k4IP2sUMn4HrAsHs0WBqlPe4RwlQNchNByi7wbcMAY4Tirkz8MqaNXdxznG7LjXgeeOE1lL_TUFtfOXdhNB_IQ05wAS6SyWtTgC3QV4GkZ1V3rKbHAI_lwyKV2fZ5OfrjVrTPTsYaJr4E7ZctQaMI_Yhmg_dNtoFcG1705dWSU4%3D | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Health economics, Oncology | 2021 | English | , Burden of illness, Clinical setting: Primary care, clinical setting: Secondary care, Epidemiological study, Literature Review, Quality of life, Retrospective database analysis, Review | |
Concerns, quality of life, access to care and productivity of the general population during the first 8 weeks of the coronavirus lockdown in Belgium and the Netherlands | ||||
Hanne van Ballegooijen 1, Lucas Goossens 2, Ralph H Bruin 3, Renée Michels 3, Marieke Krol 3 | ||||
1IQVIA, Herikerbergweg 314, 1101 CT, Amsterdam, The Netherlands. hanne.vanballegooijen@iqvia.com. 2Erasmus University Rotterdam, Erasmus School of Health Policy & Management, Rotterdam, The Netherlands. 3IQVIA, Herikerbergweg 314, 1101 CT, Amsterdam, The Netherlands. | ||||
1 IQVIA, Herikerbergweg 314, 1101 CT Amsterdam, The Netherlands. 2 Erasmus University Rotterdam, Erasmus School of Health Policy & Management, Rotterdam, The Netherlands BMC Health Services Research (2021) 21:227 PMID: 33712010 PMCID: PMC7953179 DOI: 10.1186/s12913-021-06240-7 |
||||
, Article | ||||
, Netherlands | ||||
Abstract: https://pubmed.ncbi.nlm.nih.gov/33712010/ | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Health status & patient reported outcomes, Immunology and Vaccination | 2021 | English | , Observational study, Patient questionnaire, Population Based Study, Public Health, Quality of life, Survey research | |
The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type 2 Diabetes and Established Cardiovascular Disease | ||||
Lars Holger Ehlers 1, Mark Lamotte 2, Sofia Monteiro 3, Susanne Sandgaard 4, Pia Holmgaard 4, Evan C Frary 4, Niels Ejskjaer 5 6 7 | ||||
1Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. 2IQVIA Real World Solutions, Zaventem, Belgium. 3IQVIA Real World Solutions, London, UK. 4Boehringer Ingelheim Danmark A/S, København Ø, Hovedstaden, Denmark. 5Department of Clinical Medicine, Aalborg University, Aalborg, Denmark. n.ejskjaer@rn.dk. 6Steno Diabetes Center North Denmark, Aalborg University Hospital, Aalborg, Denmark. n.ejskjaer@rn.dk. 7Department of Endocrinology, Aalborg University Hospital, Aalborg, Denmark. n.ejskjaer@rn.dk. | ||||
Diabetes Therapy https://doi.org/10.1007/s13300-021-01040-y IQVIA HEOR Zaventem Brussels PMID: 33856655 PMCID: PMC8099952 DOI: 10.1007/s13300-021-01040-y |
||||
, Denmark | ||||
Abstract: https://pubmed.ncbi.nlm.nih.gov/33856655/ | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Health economics | 2021 | English | , Clinical setting: Primary care, Cost effectiveness | |
Patient and caregiver productivity loss and indirect costs associated with cardiovascular events in Portugal | ||||
Nuno Marques 1, Laetitia Gerlier 2, Mafalda Ramos 3, Helder Pereira 4, Sérgia Rocha 5, Ana Catarina Fonseca 6, Ana André 7, Ricardo Melo 8, Eduard Sidelnikov 9 | ||||
1Department of Cardiology, Centro Hospitalar e Universitário do Algarve, Faro, Portugal. 2IQVIA, Zaventem, Belgium. 3IQVIA, Zaventem, Belgium. Electronic address: mafalda.ramos@iqvia.com. 4Department of Cardiology, Hospital Garcia de Orta, Almada, Portugal. 5Department of Cardiology, Hospital de Braga, Braga, Portugal. 6Department of Neurology, Hospital de Santa Maria, Universidade de Lisboa, Lisboa, Portugal. 7Department of Neurology, Centro Hospitalar e Universitário do Algarve, Faro, Portugal. 8Amgen SA, Portugal. 9Amgen (Europe) GmbH, Rotkreuz, Switzerland. | ||||
PMID: 33581948 DOI: 10.1016/j.repc.2020.05.019 IQVIA HEOR Zaventem Brussels Revista Portuguesa de Cardiologia Volume 40, Issue 2, February 2021, Pages 109-115. |
||||
, Article | ||||
, Portugal | ||||
Abstract: https://pubmed.ncbi.nlm.nih.gov/33581948/ | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease, Health economics | 2021 | English | , Burden of illness, Clinical setting: Primary care, Prospective study | |
Cost-effectiveness analysis of empagliflozin compared with glimepiride in patients with Type 2 diabetes in China | ||||
Ahmed Salem 1, Peng Men 2 3, Mafalda Ramos 4, Yan-Jun Zhang 5, Anastasia Ustyugova 6, Mark Lamotte 7 | ||||
1IQVIA, Real World Solutions, Zaventem 1930, Belgium. 2Department of Pharmacy, Peking University Third Hospital, Beijing 100191, China. 3Institute for Drug Evaluation, Peking University Health Science Center, Beijing 100191, China. 4IQVIA, Global HEOR, Porto Salvo 2740-266, Portugal. 5Boehringer Ingelheim, Health Economics & Outcomes Research, Government Affairs & Market Access, Shanghai 200040, China. 6Boehringer Ingelheim, CardioMetabolism Respiratory, Ingelheim am Rhein 55216, Germany. 7IQVIA, Global HEOR, Zaventem 1930, Belgium. | ||||
Journal of Comparative Effectiveness Research 2021 https://doi.org/10.2217/cer-2020-0284. PMID: 33576249 DOI: 10.2217/cer-2020-0284 |
||||
, Article | ||||
, China | ||||
Abstract: https://pubmed.ncbi.nlm.nih.gov/33576249/ | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Health economics | 2021 | English | , Clinical setting: Primary care, Cost effectiveness | |
Potential clinical and economic impact of optimised maintenance therapy on discharged patients with COPD after hospitalisation for an exacerbation in China | ||||
Ahmed Salem # 1, Heng Zhong # 2, Mafalda Ramos 1, Mark Lamotte 1, Hao Hu 3 | ||||
1Real World Evidence, IQVIA, Zaventem, Belgium. 2R&D China, AstraZeneca R&D, Shanghai, China. 3Institute of Chinese Medical Sciences, University of Macau, Macau, China haohu@um.edu.mo. #Contributed equally. | ||||
BMJ Open 2021;11:e043664. doi:10.1136/bmjopen-2020-043664 e043664. doi:10.1136/bmjopen-2020-043664 PMID: 33910947 PMCID: PMC8094343 DOI: 10.1136/bmjopen-2020-043664 |
||||
, Article | ||||
, Belgium, China | ||||
Abstract: https://pubmed.ncbi.nlm.nih.gov/33910947/ | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Respiratory disease | 2021 | English | , Clinical setting: Primary care, Cost effectiveness | |
A novel decision model to predict the impact of weight management interventions: The Core Obesity Model. | ||||
Sandra Lopes 1, Henrik H Meincke 1, Mark Lamotte 2, Anamaria-Vera Olivieri 3, Michael E J Lean 4 | ||||
1Novo Nordisk A/S Søborg Denmark. 2IQVIA Zaventem Belgium. 3IQVIA Basel Switzerland. 4Human Nutrition School of Medicine, Dentistry and Nursing Royal Infirmary University of Glasgow Glasgow UK. | ||||
Obesity Science & Practice 2021. https://doi.org/10.1002/osp4.495 |
||||
, Article | ||||
, Belgium, Switzerland | ||||
Abstract: https://pubmed.ncbi.nlm.nih.gov/34123394 | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Obesity | 2021 | English | , Clinical setting: Primary care, Cost effectiveness | |
Utilization of Healthcare Resources in Osteoarthritis: A Cost of Illness Analysis Based on Real-World Data in Italy | ||||
Colombo GL, Heiman F, Peduto I | ||||
Colombo GL: CEFAT - Department of Drug Sciences, University of Pavia, Pavia, Italy. Peduto I, Heiman F: IQVIA Solutions Italy S.r.l., Milan, Italy, | ||||
Ther Clin Risk Manag. 2021 Apr 21;17:345-356. doi: 10.2147/TCRM.S301005 |
||||
, Article | ||||
, Italy | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072261/pdf/tcrm-17-345.pdf | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Overactive bladder | 2021 | English | , Clinical setting: Primary care, Cost of illness | |
Cost-effectiveness analysis of the treatment strategies with or without opioid medications in surgery-eligible patients with osteoarthritis in Japan | ||||
Tomoyuki Takura 1, Akira Yuasa 2, Naohiro Yonemoto 2, Sven Demiya 3, Hiroyuki Matsuda 3, Nozomi Ebata 4, Koichi Fujii 4, Muneaki Ishijima 5 (rwesheorj 3) | ||||
1) Department of Healthcare Economics and Health Policy, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan 2) Health and Value, Pfizer Japan Inc., Shinjuku Bunka Quint Building, 3-22-7, Yoyogi, Shibuya-ku, Tokyo, 151-8589, Japan 3) IQVIA Solutions Japan K.K., Tokyo, Japan 4) Medical Affairs, Pfizer Japan Inc, Tokyo, Japan 5) Department of Medicine for Orthopaedics and Motor Organ, Juntendo University Graduate School of Medicine, Tokyo, Japan | ||||
PharmacoEconomics - Open |
||||
, Article | ||||
, Japan | ||||
Abstract: https://link.springer.com/article/10.1007/s41669-021-00292-5 | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2021 | English | , Cost effectiveness, Literature Review | |
Analisi di impatto sul budget sanitario italiano di gilteritinib per il trattamento della leucemia mieloide acuta FLT3+ recidivante o refrattaria | ||||
Fiorentino F, La Malfa P, Di Rienzo P | ||||
Fiorentino F: IQVIA Solutions Italy Srl, RWS | ||||
GIHTAD (2021) 14:4 |
||||
, Article | ||||
, Italy | ||||
Abstract: https://springerhealthcare.it/GIHTAD/2021/07/05/analisi-di-impatto-sul-budget-sanitario-italiano-di-gilteritinib-%E2%80%A8per-il-trattamento-della-leucemia-mieloide-acuta-flt3-recidivante-%E2%80%A8o-refrattaria/ | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Oncology | 2021 | Italian | , Budget impact, clinical setting: Secondary care | |
Utilization of Healthcare Resources in Osteoarthritis: A Cost of Illness Analysis Based on Real-World Data in Italy | ||||
Colombo GL, Heiman F, Peduto I | ||||
Colombo GL: CEFAT - Department of Drug Sciences, University of Pavia, Pavia, Italy. Peduto I, Heiman F: IQVIA Solutions Italy S.r.l., Milan, Italy, | ||||
Ther Clin Risk Manag. 2021 Apr 21;17:345-356. doi: 10.2147/TCRM.S301005 |
||||
, Article | ||||
, Italy | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072261/pdf/tcrm-17-345.pdf | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Orthopedics | 2021 | English | , Clinical setting: Primary care, Cost of illness, Retrospective database analysis | |
Trifluridine/tipiracil hydrochloride in the treatment of polytreated metastatic colorectal carcinoma: a cost-effectiveness analysis in the private payer perspective in Brazil | ||||
Fernando Meton de Alencar Camara Vieira (1); Ana Paula Ornellas de Souza Victorino (1); Kelly Borges Araújo (1); Bianca Oesterreicher (2); Pedro Vitor Pereira Lima (2); Luciana Calvo Mardegan (3); Sandro Albuquerque (3); Juliana Simões Festa de Vasconcellos (3) | ||||
1: Instituto COI de Educação e Pesquisa, Rio de Janeiro, RJ, Brasil; 2: IQVIA Solutions, Real World Insights, São Paulo, SP, Brasil; 3: Laboratórios Servier, Rio de Janeiro, RJ, Brasil. | ||||
, Article | ||||
, Brazil | ||||
Abstract: https://jbes.com.br/wp-content/uploads/2022/01/DOI_10_21115_JBES_v13_n3_p242-52.pdf | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Oncology | 2021 | Portuguese | , Cost effectiveness | |
Cost-effectiveness and budget impact analysis of a patient visit support system for blindness reduction in Japanese patients with glaucoma | ||||
Masakazu Yamada 1, Tadashi Nakano 2, Hiroyuki Matsuda 3, Seok-Won Kim 3, Yasutaka Takagi 4 (rwesheorj 3) | ||||
1) Department of Ophthalmology, Kyorin University School of Medicine, Mitaka, Japan 2) Department of Ophthalmology, The Jikei University School of Medicine, Tokyo, Japan 3) Real World Evidence Solutions, IQVIA solutions Japan, Tokyo, Japan 4) Japan Medical Affairs Group, Santen Pharmaceutical Co., Ltd, Osaka, Japan | ||||
Journal of Medical Economics |
||||
, Article | ||||
, Japan | ||||
Abstract: https://www.tandfonline.com/doi/full/10.1080/13696998.2020.1804392 | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2020 | English | , Budget impact, Cost effectiveness | |
Evaluation of the optimal position for vedolizumab in the Japanese treatment paradigm for ulcerative colitis using Markov modeling | ||||
Akihito Uda 1, Yuki Eto 1, Yuxin Li 2, Hiroyuki Matsuda 3, Sven Demiya 3, Tomoyuki Watanabe 1, Mihoko Ota 1, Ryuichi Iwakiri 1, Ataru Igarashi 4 5 (rwesheorj 3) | ||||
1) Japan Medical Office, Takeda Pharmaceutical Co. Ltd., Tokyo, Japan 2) IQVIA Solutions UK Ltd., London, UK 3) IQVIA Solutions Japan KK, Tokyo, Japan 4) Unit of Public Health and Preventive Medicine, School of Medicine, Yokohama City University, Yokohama, Kanagawa, Japan 5) Department of Health Economics and Outcomes Research, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo, Tokyo, Japan | ||||
Crohn's & Colitis 360 |
||||
, Article | ||||
, Japan | ||||
Abstract: https://academic.oup.com/crohnscolitis360/article/2/2/otaa017/5809344 | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2020 | English | , Budget impact, Cost effectiveness, Economic evaluation | |
Investigation of factors considered by health technology assessment agencies in eight countries | ||||
Akira Yuasa 1 2, Naohiro Yonemoto 1, Sven Demiya 3, Chihiro Foellscher 3, Shunya Ikeda 2 (rwesheorj 3) | ||||
1) Pfizer Japan Inc, Tokyo, Japan 2) Graduate School of Medicine, International University of Health and Welfare, 1-26, Akasaka 4-chome, Minato-ku, Tokyo, 107-8402, Japan 3) IQVIA Solutions Japan K.K., Tokyo, Japan | ||||
PharmacoEconomics - Open |
||||
, Article | ||||
, Japan | ||||
Abstract: https://link.springer.com/article/10.1007%2Fs41669-020-00235-6 | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2020 | English | , Economic evaluation | |
RWE is the Future of Clinical Research: Time to Get Onboard | ||||
Nancy A. Dreyer, | ||||
Chief Scientific Officer and Senior VP, IQVIA Real World Solutions | ||||
PharmaVOICE - March 2020 |
||||
, Article | ||||
, USA | ||||
Abstract: https://www.pharmavoice.com/article/2020-03-rwe-research/#:~:text=We've%20been%20talking%20about,tools%20are%20coming%20into%20use. | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Health status & patient reported outcomes | 2020 | English | , Economic evaluation, Literature Review, Market impact | |
Multicenter Prospective Evaluation of Parenteral Nutrition Preparation Time and Resource Utilization: 3-Chamber Bags Compared With Hospital Pharmacy-Compounded Bags | ||||
Sarah V Cogle 1 2, Robert G Martindale 3, Mafalda Ramos 4, Gregory J Roberti 5, Pamela R Roberts 6, Kaci Taylor 7, Gordon S Sacks 1 8 | ||||
1Department of Pharmacy Practice, Auburn University, Auburn, Alabama, USA. 2Department of Pharmacy, East Alabama Medical Center, Opelika, Alabama, USA. 3Department of Surgery, Oregon Health and Science University, Portland, Oregon, USA. 4IQVIA, Zaventem, Belgium. 5Department of Pharmacy, Oregon Health and Science University, Portland, Oregon, USA. 6Department of Anesthesiology, University of Oklahoma College of Medicine, Oklahoma City, Oklahoma, USA. 7Department of Pharmacy, OU Medical Center, Oklahoma City, Oklahoma, USA. 8Medical Affairs, Fresenius Kabi, LLC, Lake Zurich, Illinois, USA. | ||||
Journal of Parenteral and Enteral Nutrition Volume 0 Number 0 November 2020 1–7 DOI: 10.1002/jpen.2045 PMID: 33188572 DOI: 10.1002/jpen.2045 |
||||
, USA | ||||
Abstract: https://pubmed.ncbi.nlm.nih.gov/33188572/ | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Neurological disorders | 2020 | English | , Clinical setting: hospital, Cost effectiveness, Prospective study | |
Cost-effectiveness of empagliflozin compared with liraglutide based on cardiovascular outcome trials in Type II diabetes | ||||
Mafalda Ramos 1, Anastasia Ustyugova 2, Nikco Hau 3, Mark Lamotte 4 | ||||
1IQVIA Global HEOR, Porto Salvo 2740-266, Portugal. 2Boehringer Ingelheim International GmbH, TA CardioMetabolism Respiratory, Binger Str 173, Ingelheim am Rhein 55216, Germany. 3Boehringer Ingelheim Ltd, UK Market Access, Bracknell RG128YS, UK (at the time of the study). 4IQVIA, Global HEOR, Zaventem 1930, Belgium. | ||||
Journal of Comparative Effectiveness Research 2020. https://doi.org/10.2217/cer-2020-0071 PMID: 32573253 DOI: 10.2217/cer-2020-0071 |
||||
, Article | ||||
, UK | ||||
Abstract: https://pubmed.ncbi.nlm.nih.gov/32573253/ | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Health economics | 2020 | English | , Clinical setting: Primary care, Cost effectiveness | |
Long-Term Cost-Effectiveness Analyses of Empagliflozin Versus Oral Semaglutide, in Addition to Metformin, for the Treatment of Type 2 Diabetes in the UK | ||||
Mafalda Ramos 1, Michael H Cummings 2, Anastasia Ustyugova 3, Syed I Raza 4, Shamika U de Silva 4, Mark Lamotte 5 | ||||
1Global HEOR/Real World Solutions, IQVIA, 2740-266, Porto Salvo, Portugal. 2Academic Department of Diabetes and Endocrinology, Queen Alexandra Hospital, Portsmouth, PO6 3LY, Hampshire, UK. 3Boehringer Ingelheim International GmbH, 55216, Ingelheim Am Rhein, Germany. 4Boehringer Ingelheim Ltd., Bracknell, RG12 8YS, Berkshire, UK. 5Global HEOR/Real World Solutions, IQVIA, 1930, Zaventem, Belgium. Mark.lamotte@iqvia.com. | ||||
Diabetes Therapy 2020; 11(9), 2041-2055; https://doi.org/10.1007/s13300-020-00883-1. PMID: 32700188 PMCID: PMC7434815 DOI: 10.1007/s13300-020-00883-1 |
||||
, Article | ||||
, UK | ||||
Abstract: https://pubmed.ncbi.nlm.nih.gov/32700188/ | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Health economics | 2020 | English | , Clinical setting: Primary care, Cost effectiveness | |
External Validation of the Core Obesity Model to Assess the Cost Effectiveness of Weight Management Interventions | ||||
Sandra Lopes 1, Pierre Johansen 2, Mark Lamotte 3, Phil McEwan 4, Anamaria-Vera Olivieri 5, Volker Foos 4 | ||||
1Novo Nordisk A/S, Søborg, Denmark. snlb@novonordisk.com. 2Novo Nordisk A/S, Søborg, Denmark. 3IQVIA, Zaventem, Belgium. 4Health Economics and Outcomes Research Ltd, Cardiff, UK. 5IQVIA, Basel, Switzerland. | ||||
Pharmacoeconomics 2020 https://doi.org/10.1007/s40273-020-00941-3 + Pharmacoeconomics. 2021 Jan;39(1):137-138. doi: 10.1007/s40273-020-00982-8. Epub 2020 Nov 30 |
||||
, Article | ||||
, Belgium, Denmark, Switzerland, UK | ||||
Abstract: https://pubmed.ncbi.nlm.nih.gov/32656686/ | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Obesity | 2020 | English | , Clinical setting: Primary care, Cost effectiveness | |
DOES INCLUDING ACUTE PANCREATITIS AS A COMPLICATION HAVE AN IMPACT ON COST-EFFECTIVENESS ANALYSES USING THE IQVIA CORE DIABETES MODEL? | ||||
Monteiro S, Ramos M, Lamotte M | ||||
IQVIA HEOR Zaventem Brussels | ||||
ISPOR US 2020 Orlando. Value in Health, Volume 23, Issue 5, S1 (May 2020) Code PDB44. |
||||
, Poster | ||||
, UK | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Health economics | 2020 | English | , Clinical setting: Primary care, Cost effectiveness | |
IMPACT OF USING DIFFERENT TYPES OF HBA1C PROGRESSION IN THE IQVIA CORE DIABETES MODEL. | ||||
Ramos M, Monteiro S, Lamotte M | ||||
IQVIA HEOR Zaventem Brussels | ||||
ISPOR US 2020 Orlando Value in Health, Volume 23, Issue 5, S1 (May 2020) Code PDB52. |
||||
, Poster | ||||
, UK | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Health economics | 2020 | English | , Clinical setting: Primary care, Cost effectiveness | |
Three Asian Type 2 Diabetes cardiovascular risk equations simulation using the IQVIA Core Diabetes Model | ||||
Ryo Mitsuo 1, Sven Demiya 1, Adeeb Tawseef 1, Raf De Moor 1, M Ramos, M Lamotte (rwesheorj 1) | ||||
IQVIA HEOR Zaventem Brussels | ||||
Japan Diabetes Society 2020 Annual Meeting |
||||
, Poster | ||||
, Asia Pacific, Japan | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Health economics | 2020 | English | , Clinical setting: Primary care, Cost effectiveness | |
CONTRASTING THREE TYPE 2 DIABETES CARDIOVASCULAR RISK EQUATIONS FOR EAST ASIA WITH UKPDS82 USING THE IQVIA CORE DIABETES MODEL. | ||||
Ramos M, Monteiro S, Olivieri AV, Lamotte M. | ||||
IQVIA HEOR Zaventem Brussels | ||||
ISPOR US 2020 Orlando. Value in Health, Volume 23, Issue 5, S1 (May 2020) Code PDB56 |
||||
, Poster | ||||
, Asia Pacific | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Health economics | 2020 | English | , Clinical setting: Primary care, Cost effectiveness | |
Does Including EGFR Along to HBA1C As a Driver of Treatment Switch Changes Outcomes in Cost-Effectiveness Analyses in Type 2 Diabetes? | ||||
Ramos M, Monteiro S, Lamotte M | ||||
IQVIA HEOR Zaventem Brussels | ||||
ISPOR Europe 2020 Virtual conference Milano Nov 16-19 Abstract ID# 108179. |
||||
, Poster | ||||
, UK | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Health economics | 2020 | English | , Clinical setting: Primary care, Cost effectiveness | |
The Cost-Effectiveness of Empagliflozin in Type 2 Diabetes in Denmark, Incorporating Cardiovascular Outcomes | ||||
Ehlers LH, Lamotte M, Monteiro S, Sandgaard S, Holmgaard P, Frary EC, Staehr P, Ejskjaer N. | ||||
IQVIA HEOR Zaventem Brussels | ||||
ISPOR Europe 2020 Virtual conference Milano Nov 16-19 Abstract ID# 107114 |
||||
, Poster | ||||
, Denmark | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Health economics | 2020 | English | , Clinical setting: Primary care, Cost effectiveness | |
Cost-Effectiveness of the FreeStyle Libre System versus Self-Monitoring of Blood Glucose in People with Type 2 Diabetes on Insulin Treatment not Reaching Glycemic Goals in Sweden. | ||||
Jendle J, Eeg-Olofsson K, Svensson AM, Franzen S, Lamotte M, Levrat-Guillen F. | ||||
IQVIA HEOR Zaventem Brussels | ||||
American Diabetes Association’s (ADA’s) 81st Scientific Sessions. Poster presentation number 135-LB |
||||
, Poster | ||||
, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Health economics | 2020 | English | , Clinical setting: Primary care, Cost effectiveness | |
Cost-utility model for 2nd generation treatment of chronic HCV in general population: impact of EASL recommendations in 2016 and 2018 | ||||
Natlia Pascual-Argent (1,2); Carlos Crespo (1,3); Laura Planellas (4); Mriam Solozabal (4), Nria Perulero (4); Jaume Puig-Junoy (1,2) | ||||
(1) UPF Barcelona School of Management; (2) Dept. Economa y Empresa CRES UPF; (3) Universitat de Barcelona; (4) HEOR-RWE, IQVIA Spain | ||||
XXXIX Jornadas de Economa de la Salud. Albacete, 12 al 14 de junio de 2019 |
||||
, Poster | ||||
, Spain | ||||
Abstract: http://www.aes.es/jornadas/pdfs/Jornadas_AES_2019-Libro_abstracts.pdf | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment, Health economics, Infectious disease | 2019 | Spanish | , Clinical setting: hospital, Cost effectiveness | |
Health economic effects of the updated foot ulcer submodel | ||||
Monteiro S1, Ramos M2, Lamotte M2 | ||||
1 IQVIA, London, UK 2 IQVIA, Zaventem, Belgium | ||||
ISPOR, Copenhagen, Denmark, 4-6 November 2019 |
||||
, Poster | ||||
, UK | ||||
Abstract: https://doi.org/10.1016/j.jval.2019.09.899 | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Health economics | 2019 | English | , Cost effectiveness | |
The clinical and economic impact of adding an adherence module to the IQVIAcore diabetes model | ||||
Ramos M1, Monteiro S2, Altrabsheh E2, Lamotte M1 | ||||
1 IQVIA, Zaventem, Belgium 2 IQVIA, London, UK | ||||
ISPOR, Copenhagen, Denmark, 4-6 November 2019 |
||||
, Poster | ||||
, Germany | ||||
Abstract: https://doi.org/10.1016/j.jval.2019.09.943 | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Health economics | 2019 | English | , Cost effectiveness, Survey research | |
The cost effectiveness of Enoxaparin in the previon of venous thromboembolism in patients undergoing major surgery in Egypt | ||||
Farag A1, Abdel Moety H1, Hassan L2, Pathak P3, Lamotte M4, Levorsen A5 | ||||
1 Cairo University, Cairo, Egypt 2 Alexandria University, Alexandria, Egypt 3 IQVIA, Dubai, United Arab Emirates 4 IQVIA, Zaventem, Belgium 5 Sanofi, Global, France | ||||
ISPOR, Copenhagen, Denmark, 4-6 November 2019 |
||||
, Poster | ||||
, Egypt | ||||
Abstract: https://doi.org/10.1016/j.jval.2019.09.2604 | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Orthopedics | 2019 | English | , Cost effectiveness | |
Cost-effectiveness analysis of the SAPIEN 3 TAVI valve compared with surgery in intermediate-risk patients | ||||
Goodall G1, Lamotte M2, Ramos M2, Maunoury F3, Pejchalova B1, de Pouvourville G4 | ||||
1 Edwards Lifesciences S.A., Nyon, Switzerland 2 IQVIA, Zaventem, Belgium 3 Statesia, Le Mans, France 4 ESSEC Business School, Cergy Pontoise, France | ||||
J Med Econ. 2019 Apr;22(4):289-296. doi: 10.1080/13696998.2018 |
||||
, Article | ||||
, France | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/30547704 | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease, Health economics | 2019 | English | , Cost effectiveness | |
Health economic value of blood in Ivory coast: The case of maternal bleeding | ||||
Sekongo YM1, Asamoah-Akuoko L2, Owusu-Ofori SPO3, Lamotte M4, Bah A5, Dierick K5 | ||||
1 DEA Biologie Humaine et Tropicale Unité de Thérapeutique Transfusionnelle Centre National de Tranfusion Sanguine DU de Biologie Transfusionnelle DU Gestion des infections et soins complementaires en Onco-Hématologie DU BIOSAS DU Reparation juridique du Do, Abidjan,Yvory Coast 2 National Blood Service, Accra, Ghana 3 Komfo Anokye Teaching Hospital, Kumasi, Ghana 4 IQVIA, Zaventem, Belgium 5 Terumo BCT, Zaventem, Belgium | ||||
ISPOR, Copenhagen, Denmark, 4-6 November 2019 |
||||
, Poster | ||||
, Ivory Coast | ||||
Abstract: https://doi.org/10.1016/j.jval.2019.09.1429 | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Hematology | 2019 | English | , Cost analysis, Literature Review | |
Health economic vale of blood in Ghana: The case of maternal bleeding | ||||
Owusu-Ofori SPO1, Asamoah-Akuoko L2, Lamotte M3, Bah A4, Dierick K4 | ||||
1 Komfo Anokye Teaching Hospital, Kumasi, Ghana 2 National Blood Service, Accra, Ghana 3 IQVIA, Zaventem, Belgium 4 Terumo BCT, Zaventem, Belgium | ||||
ISPOR, Copenhagen, Denmark, 4-6 November 2019 |
||||
, Poster | ||||
Abstract: https://doi.org/10.1016/j.jval.2019.09.1964 | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Hematology | 2019 | English | , Cost analysis, Survey research | |
Health economic value of blood in Sub-Saharan: The case of maternal bleeding | ||||
Owusu-Ofori SPO1, Sekongo YM2, Rajab JA3, Asamoah-Akuoko L4, Magutu V5, Lamotte M6, Bah A7, Dierick K7 | ||||
1 Komfo Anokye Teaching Hospital, Kumasi, Ghana 2 DEA Biologie Humaine et Tropicale Unité de Thérapeutique Transfusionnelle Centre National de Tranfusion Sanguine DU de Biologie Transfusionnelle DU Gestion des infections et soins complementaires en Onco-Hématologie DU BIOSAS DU Reparation juridique du Do, Abidjan, Yvory Coast 3 Haematology & Blood Transfusion Unit, Department of Human Pathology, School of Medicine, College of Health Sciences, University of Nairobi, Kenya 4 National Blood Service, Accra, Ghana 5 Department of Pathology Agar Khan Hospital, Nairobi, 110, Kenya 6 IQVIA, Zaventem, Belgium 7 Terumo BCT, Zaventem, Belgium | ||||
ISPOR, Copenhagen, Denmark, 4-6 November 2019 |
||||
, Poster | ||||
Abstract: https://doi.org/10.1016/j.jval.2019.09.2059 | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Hematology | 2019 | English | , Cost analysis, Survey research | |
Patient and caregiver productivity loss and indirect costs associated with cardiovascular events in Europe | ||||
Kotseva K1, Gerlier L2, Sidelnikov E3, Kutikova L3, Lamotte M2, Amarenco P4, Annemans L5 | ||||
1 Department of Cardiovascular Medicine, National Heart and Lung Institute, Imperial College London, UK 2 IQVIA, Zaventem, Belgium 3 Amgen (Europe) GmbH, Rotkreuz, Switzerland 4 Department of Neurology and Stroke Centre, Bichat Hospital, Paris, France 5 University of Ghent, Belgium | ||||
Eur J Prev Cardiol. 2019 Jul;26(11):1150-1157. |
||||
, Article | ||||
, Belgium, France, Poland, Portugal, Spain, Switzerland, UK | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/30955367 | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease, Health economics | 2019 | English | , Burden of illness, Clinical setting: Primary care, direct to patient research, Observational study | |
The value of blood in sub-Saharan Africa | ||||
Magutu V1, Rajab A2, Asamoah-Akuoko L3, Lamotte M4, Bah A5, Dierick K5 | ||||
1 Department of Pathology Agar Khan Hospital, Nairobi, 110, Kenya 2 Haematology & Blood Transfusion Unit, Department of Human Pathology, School of Medicine, College of Health Sciences, University of Nairobi, Nairobi, Kenya 3 National Blood Service, Accra, Ghana 4 IQVIA, Zaventem, Belgium 5 Terumo BCT, Zaventem, Belgium | ||||
ISPOR, Copenhagen, Denmark, 4-6 November 2019 |
||||
, Poster | ||||
Abstract: https://doi.org/10.1016/j.jval.2019.09.2084 | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Hematology | 2019 | English | , Cost analysis, Survey research | |
Insulin glargine compared to neutral protamine Hagedorn (NPH) insulin in patients with type-2 diabetes uncontrolled with oral anti-diabetic agents alone in Hong Kong: a cost-effectiveness analysis | ||||
Lau E1, Salem A2, Chan JCN1, So WY1, Kong A1, Lamotte M2, Luk A1 | ||||
1 Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong, SAR China 2 IQVIA, Zaventem, Belgium | ||||
Cost Eff Resour Alloc. 2019 Jul 2;17:13. |
||||
, Article | ||||
, Hong Kong | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/31303866 | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Health economics | 2019 | English | , Cost effectiveness | |
The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood | ||||
Kent S1, Becker F1, Feenstra T2,3, Tran-Duy A4, Schlackow I1, Tew M4, Zhang P5, Ye W6, Lizheng S7, Herman W6, McEwan P8, Schramm W9, Gray A1, Leal J1, Lamotte M10, Willis M11, Palmer AJ4,12, Clarke P13,14 | ||||
1 Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK 2 National Institute for Public Health and the Environment (RIVM), Centre for Nutrition, Prevention and Health Services Research, Bilthoven, The Netherlands 3 University of Groningen, Faculty of Science and Engineering, Groningen Research Institute of Pharmacy, Groningen, The Netherlands 4 Centre for Health Policy, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia 5 Division of Diabetes Translation, Centres for Disease Control and Prevention, Atlanta, US 6 School of Public Health, University of Michigan, Ann Arbor, US 7 Department of Health Management and Policy, School of Public Health and Tropical Medicine, Tulane University, New Orleans, US 8 Centre for Health Economics, Swansea University, Swansea, UK 9 GECKO Institute, Heilbronn University, Heilbronn, Germany 10 IQVIA, Zaventem, Belgium 11 The Swedish Institute for Health Economics, Lund, Sweden 12 Menzies Institute for Medical Research, The University of Tasmania, Hobart, Australia 13 Health Economics Research Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK 14 Centre for Health Policy, Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, Australia | ||||
Pharmacoeconomics. 2019 Nov;37(11):1305-1312. |
||||
, Article | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/31347104 | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Health economics | 2019 | English | , Retrospective database analysis | |
Assessing the Burden of Type 2 Diabetes in China Considering the Current Status-Quo Management and Implications of Improved Management Using a Modeling Approach | ||||
Foos V1, Wang K2, McEwan P3, Zhang Y2, Xin P2, Jiang X2, Qu S4, Xiong T4, De Moor R1, Ramos M1, Lamotte M1, Ji L5 | ||||
1 IQVIA, Zaventem, Belgium 2 Lilly Suzhou Pharmaceutical Co, Ltd, Shanghai, China 3 Centre for Health Economics, Swansea University, Wales, England, UK 4 RWE Solutions & HEOR, QuintilesIMS, Shanghai, China 5 Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China | ||||
Value Health Reg Issues. 2019 May;18:36-46. |
||||
, Article | ||||
, China | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/30419449 | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Health economics | 2019 | English | , Cost effectiveness | |
The cost-effectiveness of physical activity in the management of COPD patients in the UK | ||||
Ramos M1, Lamotte M1, Gerlier L1, Svangren P2, Miquel-Cases A3, Haughney J4 | ||||
1 IQVIA, Zaventem, Belgium 2 Core Respiratory, Global Product and Portfolio Strategy - Global Payer Evidence and Pricing, AstraZeneca Gothenburg R&D, Mölndal, Sweden 3 Global Price and Reimbursement, Global Payer Evidence and Pricing, AstraZeneca Gothenburg R&D, Cambridge, UK 4 Academic Primary Care Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK. | ||||
Int J Chron Obstruct Pulmon Dis. 2019 Jan 15;14:227-239 |
||||
, Article | ||||
, Scotland | ||||
Abstract: doi: 10.2147/COPD.S181194. eCollection 2019 | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Respiratory disease | 2019 | English | , Cost effectiveness | |
Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease | ||||
Ramos M1, Foos V1, Ustyugova A2, Hau N3, Gandhi P4, Lamotte M1 | ||||
1 IQVIA, Zaventem, Belgium 2 Boehringer Ingelheim International GmbH, Ingelheim, Germany 3 Boehringer Ingelheim Ltd, Bracknell, UK 4 Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, US | ||||
Diabetes Ther. 2019 Dec;10(6):2153-2167 |
||||
, Article | ||||
, UK | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/31602601 | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Health economics | 2019 | English | , Cost effectiveness | |
Advancing glycemic management in people with diabetes | ||||
Aitken M1, Villa P1, Lamotte M1, Tewary V1, Ramos M1 | ||||
1 IQVIA, Zaventem, Belgium | ||||
with paper on the IQVIA institute web page |
||||
, Article | ||||
Abstract: https://www.iqvia.com/insights/the-iqvia-institute/reports/advancing-glycemic-management-in-people-with-diabetes | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Health economics | 2019 | English | , Cost effectiveness | |
Cost-offsets in relapsed/refractory multiple myeloma and resource consumption derived from Italian real practice | ||||
Ripellino C, Pegoraro V, Heiman F | ||||
Ripellino C: HEOR Consultant Freelance, Milan, Italy. Pegoraro V: Medical Writer & HEOR Consultat, IQVIA, RWS, Milan, Italy. Heiman F: HEOR Engagement Manager, IQVIA, RWS, Milan, Italy | ||||
CLINICO ECONOMICS ITALIAN ARTICLES ON OUTCOMES RESEARCH / VOL 14 / YEAR 2019 / PAG. 55-64 |
||||
, Article | ||||
, Italy | ||||
Abstract: http://www.clinicoeconomics.eu/articles/flipbook/14_2019_55-64/ | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Oncology | 2019 | Italian | , Cost analysis | |
Cost-effectiveness of de-escalation from micafungin versus escalation from fluconazole for systemic candida infections in China | ||||
Dechang Chen, Xianyao Wan, Eliza Kruger, Can Chen, Xiaomeng Yue, Liang Wang, Jiuhong Wu | ||||
IQVIA, Department of Critical Care Medicine, Shanghai Ruijin Hospital Affiliated To Jiaotong University, School of Medicine, Shanghai | ||||
Journal of Medical Economics |
||||
, Article | ||||
, China | ||||
Abstract: http://www.tandfonline.com/doi/abs/10.1080/13696998.2017.1417312 | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Infectious disease | 2018 | English | , Cost effectiveness | |
A cost–benefit analysis of smoking cessation prescription coverage from a US payer perspective | ||||
Baker CL, Ding Y, Ferrufino CP, Kowal S, Tan J, Subedi P. A | ||||
Baker, Subedi: Pfizer; Ferrufino, Kowal and Tan: IQVIA | ||||
ClinicoEconomics and outcomes research |
||||
, Article | ||||
, USA | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6052927/pdf/ceor-10-359.pdf | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2018 | English | , Cost benefit | |
The Effect of Medicare's Annual Wellness Visit on Preventive Care for the Elderly | ||||
Miao Jiang; Danny Hughes; Wenyi Wang | ||||
Miao Jiang (IQVIA); Danny Hughes (Georgia Tech and Neiman HPI); Wenyi Wang (Medstar) | ||||
Preventive Medicine |
||||
, Article | ||||
, USA | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Health policy | 2018 | English | , Observational study, Population Based Study, Public Health, Retrospective cohort analysis | |
A retrospective study to assess resource utilization and costs in patients with post-stroke spasticity in the United Kingdom | ||||
Raluy-Callado M, Cox A, MacLachlan S, Bakheit AM, Moore AP, Dinet J & Gabriel S | ||||
Evidera | ||||
Current Medical Research and Opinion |
||||
, Article | ||||
, UK | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2018 | English | , Retrospective database analysis | |
Assessing and modeling organizational impact of tilmanocept in performing sentinel lymph node biopsy in France | ||||
Clément Le Dissez1, Pascal Paubel2, Frédéric Courbon3, Rémy Herve4, Mark Rance5, Marie-Aude Courteille6 | ||||
1IQVIA Opération France, Paris, La Défense ; 2Inserm UMR S 1145, Institut Droit et Santé, faculté de pharmacie de Paris, Université Paris Descartes, Sorbonne Paris Cité, 4 avenue de l’observatoire, 75006 Paris, France ; 3 Department of Medical Imaging, Institut Universitaire du Cancer Toulouse-Oncopole, Toulouse, France ; 4 Department of Pharmacy, Institute of Cancerology Gustave Roussy, University of Paris-Sud, Villejuif, France ; 5Norgine, Corporate ; 6Norgine, France | ||||
, Poster | ||||
, France | ||||
Condition | Year | Language | Analysis type | |
, Clinical practice, Health economics, Oncology | 2018 | English | , Budget impact, Literature Review, Public Health | |
LIMITATIONS AND EXPECTED CHALLENGES OF CAR-T ECONOMIC EVALUATION. | ||||
Allou A*, Carette J*, Minacori R*, Touahmia S*, Bourguignon S*, Troubat A*, Maurel F* | ||||
IQVIA France - RWI | ||||
ISPOR 2018 |
||||
, Poster | ||||
, France | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment, Health economics, Hematology | 2018 | English | , Cost effectiveness, Market impact, Review | |
WHAT INTERPRETATION OF ICERS IN ORPHAN DISEASES? A FRENCH EXAMPLE. | ||||
Moutier Hélène; Bourguignon Sandrine; Maurel Frédérique; Bodaghi Charles | ||||
RWI IQVIA France | ||||
ISPOR 2018 |
||||
, Poster | ||||
, France | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment, Health economics, Pricing and reimbursement, Rare Diseases | 2018 | English | , Cost effectiveness, Pricing & Reimbursement, Willingness to pay | |
Patient and caregiver productivity loss and indirect costs associated with cardiovascular events in Europe. | ||||
Kotseva K1, Gerlier L2, Sidelnikov E3, Kutikova L3, Lamotte M2, Annemans L4, Amarenco P5 | ||||
1 Imperial College London, London, United Kingdom 2 IQVIA, Zaventem, Belgium 3 Amgen Europe GmbH, Zug, Switzerland 4 Ghent University, Ghent, Belgium 5 Hospital Bichat-Claude Bernard, Paris, France | ||||
European Society of Cardiology (ESC) Congress, 2018, Munich, Germany |
||||
, Poster | ||||
, Belgium, France, Poland, Portugal, Spain, Switzerland, UK | ||||
Abstract: https://esc365.escardio.org/Congress/ESC-Congress-2018/Poster-Session-3-Health-economics/176943-patient-and-caregiver-productivity-loss-and-indirect-costs-associated-with-cardiovascular-events-in-europe | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease, Health economics | 2018 | English | , Burden of illness, Cost of illness | |
Patient and caregiver indirect costs after acute cardiovascular events in Europe. | ||||
Sidelnikov E1, Gerlier L2, Kutikova L1, Amarenco P3, Kotseva K4, Annemans L5 | ||||
1 Amgen (Europe) GmbH, Zug, Switzerland 2 IQVIA, Zaventem, Belgium 3 Paris-Diderot-Sorbonne University, Paris, France 4 National Heart & Lung Institute, Imperial College London, London, UK 5 Ghent University, Ghent, Belgium | ||||
ISPOR 21st Annual European Congress, 2018, November 10-14, Barcelona, Spain |
||||
, Oral presentation | ||||
, Austria, Bulgaria, Croatia, Czech, Denmark, Finland, Germany, Greece, Italy, Norway, Romania, Slovakia, Slovenia | ||||
Abstract: https://tools.ispor.org/ScientificPresentationsDatabase/Presentation/84816?pdfid=58963 | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease, Health economics | 2018 | English | , Burden of illness, Cost of illness | |
ECONOMIC IMPACT OF THE PATIENT BLOOD MANAGEMENT FROM A FRENCH NATIONAL PAYER AND HOSPITAL PERSPECTIVES IN FRANCE | ||||
Vasilescu L , Champs F-O1, Durand-Zaleski I | ||||
1 IQVIA France - RWI, 2 URCEco - Hôpital de l'Hôtel Dieu, Paris France | ||||
ISPOR 2018 |
||||
, Poster | ||||
, France | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2018 | English | , Budget impact, Economic evaluation | |
The health economic impact of optimizing post-hospitalization management for an exacerbation in COPD patients in China. | ||||
Salem A1, Ramos M1, Hu H2, Zhong H3, Lamotte M1 | ||||
1 IQVIA, Zaventem, Belgium 2 University of Macau, Macau, China 3 AstraZeneca, Shanghai, China | ||||
, Poster | ||||
, China | ||||
Abstract: https://tools.ispor.org/ScientificPresentationsDatabase/Presentation/83455 | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Respiratory disease | 2018 | English | , Cost analysis, Cost effectiveness | |
The health economic impact of optimizing post-hospitalization management for an exacerbation in COPD patients in China. | ||||
Salem A, Ramos M, Hu H, Zhong H, Lamotte M | ||||
IQVIA, Zaventem, Belgium | ||||
ISPOR Asia Pacific, 2018, September 8-11, Tokyo, Japan |
||||
, Poster | ||||
, China | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Respiratory disease | 2018 | English | , Cost effectiveness | |
The cost-effectiveness of physical activity in the management of COPD patients in the UK. | ||||
Ramos M, Lamotte M, Gerlier L, Svangren P, Cases A M, Haughney J | ||||
IQVIA, Zaventem, Belgium | ||||
, Poster | ||||
, UK | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Respiratory disease | 2018 | English | , Cost effectiveness | |
The relationship of predicted benefits in life expectancy and quality adjusted life expectancy for improved glucose control in type 2 diabetes simulation modeling. | ||||
Ramos M, Foos V, McEwan P, Lamotte M | ||||
IQVIA, Zaventem, Belgium | ||||
ISPOR 20th Annual European Congress, 2017, November 4-8, Glasgow, Scotland |
||||
, Poster | ||||
, USA | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Health economics | 2018 | English | , Cost effectiveness | |
Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge. | ||||
Palmer AJ1, Si L1, Tew M2, Hua X2, Willis MS3, Asseburg C3, McEwan P4, Leal J5, Gray A5, Foos V6, Lamotte M6, Feenstra T7, 8, O’Connor PC 9, Brandle M 10, Smolen HJ11, Gahn JC11, Valentine WJ12, Pollock RF12, Breeze P13, Brennan A13, Pollard D13, Ye W14, Herman WH15, Isaman DJ14, Kuo S16, Laiteerapong N17, Tran-Duy A2, Clarke PM2 | ||||
1 University of Tasmania, Hobart, Tasmania, Australia 2 University of Melbourne, Melbourne, Victoria, Australia 3 The Swedish Institute for Health Economics, Lund, Sweden 4 Health Economics and Outcomes Research Ltd., Cardiff, UK 5 University of Oxford, Oxford, UK 6 IQVIA, Zaventem, Belgium 7 National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands 8 Groningen University, Groningen, The Netherlands 9 HealthPartners Institute and HealthPartners Center for Chronic Care Innovation, Minneapolis, MN, USA 10 Kantonsspital St. Gallen, St. Gallen, Switzerland 11 Medical Decision Modeling Inc., Indianapolis, IN, USA 12 Ossian Health Economics and Communications, Basel, Switzerland 13 University of Sheffield, Sheffield, UK 14 University of Michigan, Ann Arbor, MI, USA 15 University of Michigan, Ann Arbor, MI, USA 16 University of Michigan, Ann Arbor, MI, USA 17 University of Chicago, Chicago, IL, USA | ||||
Value in Health, 2018, 21(6): 724-731 |
||||
, Article | ||||
, International | ||||
Abstract: https://doi.org/10.1016/j.jval.2018.02.002 | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Health economics | 2018 | English | , Cost effectiveness | |
Review and Validation of Cardiovascular Risk Prediction Models in East Asian Populations. | ||||
Foos V, McEwan P, Lamotte M | ||||
IQVIA, Zaventem, Belgium | ||||
Value in Health, Volume 21, Supplement 1, May 2018, Page S220 |
||||
, Poster | ||||
, USA | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Health economics | 2018 | English | , Cost effectiveness | |
Comparative Analysis of the Market Penetration of Personalised Medicine Drugs Under the Conditions of AMNOG | ||||
Fischer T, Bonduelle D, Antoni B | ||||
IQVIA Commercial GmbH & Co. OHG, Munich, Germany | ||||
, Abstract | ||||
, Germany | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Health policy | 2018 | German | , Market impact | |
Overview of German AMNOG Dossiers with Price Analysis Before and After Early Benefit Assessment | ||||
Tremmel M, Batscheider A, Bocuk D, Roxlau T, Antoni B, Elena Mihaylova, Bonduelle D | ||||
IQVIA Commercial GmbH & Co. OHG, Munich, Germany IQVIA RDS Bulgaria EOOD, Sofia, Bulgaria | ||||
, Abstract | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Health policy, Pricing and reimbursement | 2018 | English | , Pricing & Reimbursement, Review | |
The Impact of Label Extensions on the Reimbursed Price of Pharmaceutical Products Assessed According to §35A SGB V in Germany Oncological and Metabolic Diseases | ||||
Schmalhofer C, Eheberg D, Tremmel M, Bocuk D, Roxlau T, Antoni B, Bonduelle D | ||||
IQVIA Commercial GmbH & Co. OHG, Munich, Germany | ||||
, Abstract | ||||
, Germany | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Health policy, Metabolic Disorders , Oncology, Pricing and reimbursement | 2018 | English | , Cost analysis, Pricing & Reimbursement | |
DERMATOLOGY AS AN EXAMPLE Originator and Generic Market Access Pretection Strategies in Germany Using Dermatology as an Example | ||||
Greiner RA, Antoni B, Batscheider A, Bonduelle D Roxlau T, Stratil AS | ||||
IQVIA Commercial GmbH & Co. OHG, Munich, Germany | ||||
, Abstract | ||||
, Germany | ||||
Condition | Year | Language | Analysis type | |
, Dermatology, Health economics | 2018 | English | , Market impact | |
Duration of Inability to Work in Depression Patients Treated in General or Psychiatric Practices in Germany | ||||
Kostev K, Dombrowski S, Konrad M, Bohlken J | ||||
IQVIA, Frankfurt am Main, Germany FOM University of Applied Sciences, Frankfurt am Main, Germany Praxis für Neurologie und Psychiatrie, Berlin, Germany | ||||
, Abstract | ||||
, Germany | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Mental health | 2018 | English | , Real World Data, Retrospective cohort analysis | |
Potential Impact of Changes to Basket of Comparator Countries from PMPRB7 to PMPRB12 has on Canadian Product List Prices | ||||
van Doorn-Drennan, J. 1, Minhas, J. 1, Millson, B. 1, McCormick, J. 1 | ||||
1 IQVIA, Kanata, ON, Canada | ||||
ISPOR 23rd Annual International Meeting, May 19-23, 2018, Baltimore, MD, USA |
||||
, Canada | ||||
Abstract: http://imsbrogancapabilities.com/pdf/rwe/pmprb-ispor-poster-print.pdf | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2018 | English | ||
Dutch health state utilities for infertility and subfertility. | ||||
Krol M, Nap A, Michels RM, Veraart CPWM, Goossens LMA | ||||
IQVIA, Netherlands | ||||
ISPOR 21st Annual European Congress, 2018, November 10-14, Barcelona, Spain |
||||
, Abstract | ||||
, Netherlands | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Health status & patient reported outcomes | 2018 | English | , Quality of life, Utility analysis | |
Epidemiologic and economic burden of HPV diseases in Spain: implication of additional 5 types from the 9-valent vaccine. | ||||
López N1, Torné A2, Franco A3, San-Martin M1, Viayna E4, Barrull C4, Perulero N4. | ||||
1Medical Affairs, MSD, Madrid, Spain.22Gynecologic Oncology Unit, Institut Clinic of Gynecology, Obstetrics and Neonatology (ICGON), Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine, University of Barcelona, Barcelona, Spain.33Diagnostic Unit of Urology, Clinic Institute of Nephrology and Urology (ICNU) Hospital Clínic Barcelona, University of Barcelona, Barcelona, Spain.4Health Economics and Outcomes Research, Real World Insights, IQVIA, Barcelona, Spain. | ||||
Infect Agent Cancer. 2018 May 2;13:15. |
||||
, Article | ||||
, Spain | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/29743937 | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Immunology and Vaccination, Infectious disease, Oncology | 2018 | English | , Burden of illness, clinical setting: Secondary care, Literature Review, Review, Survey research | |
Análisis coste-utilidad de antivirales de acción directa de segunda generación para la hepatitis C: Una revisión sistemática. | ||||
Puig-Junoy J123, Pascual-Argente N23, Puig-Codina L2, Planellas L4, Solozabal M4. | ||||
1Pompeu Fabra University (UPF), Department of Economics and Business; 2UPF Barcelona School of Management; 3Center for Research in Health and Economics (CRES-UPF); 4IQVIA, Real-World Insights, Barcelona | ||||
XXXVIII Jornadas de Economía de la Salud, Gran Canaria 2018 |
||||
, Poster | ||||
, Spain | ||||
Abstract: http://www.aes.es/jornadas/es/ | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Infectious disease | 2018 | Spanish | , Clinical setting: hospital, Literature Review, Review, Survey research | |
Cost-utility analysis of second-generation direct-acting antivirals for hepatitis C: a systematic review | ||||
Jaume Puig-Junoya,b,c, Natàlia Pascual-Argenteb,c, Lluc Puig-Codinab, Laura Planellasd, Míriam Solozabald | ||||
aDepartment of Economics and Business (UPF), Pompeu Fabra University, Barcelona, Spain; bUPF Barcelona School of Management, Pompeu Fabra University, Barcelona, Spain; cUPF Center for Research in Health and Economics (CRES-UPF), Pompeu Fabra University, Barcelona, Spain; dHEOR-RWI, IQVIA Spain | ||||
Expert Review of Gastroenterology and Hepatology. Volume 12, 2018 - Issue 12 |
||||
, Article | ||||
, Spain | ||||
Abstract: https://www.tandfonline.com/doi/abs/10.1080/17474124.2018.1540929?journalCode=ierh20 | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Infectious disease | 2018 | English | , Clinical setting: hospital, Literature Review, Review | |
DIFFERENCES AND DECISION DRIVERS IN THE HTA-OUTCOME CATEGORY LOWER BENEFIT BETWEEN IQWIG AND G-BA ASSESSMENT IN THE GERMAN AMNOG PROCESS | ||||
von Hein, Mirko; Peters, Ann-Sophie; Jakovac, Mihael | ||||
QuintilesIMS | ||||
ISPOR 20th Annual European Congress |
||||
, Poster | ||||
, Germany | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2017 | English | , Public Health | |
The cost-effectiveness of IVF treatments Gonal-f® versus HP-hMG in the United Arab Emirates (UAE). | ||||
Mohamed E1, Garg N, Madkour W, Zaheer H, Sayed W, Noah B, Fakih A, Farag T, Wadie G, Jain R, Prasanna R, van Gils C2 | ||||
1 Dubai gynaecology & fertility center , UAE 2 Real-World Evidence Solutions QuintilesIMS, Belgium | ||||
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual European Congress, 2017, Nov 4 - 8, Glasgow, Scotland, United Kingdom |
||||
, Abstract | ||||
, UAE | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2017 | English | , clinical setting: Secondary care, Cost effectiveness | |
Epidemiologic and economic burden of HPV-related diseases in Spain: Potential benefit of adding 5 additional types in the nonavalent vaccine. | ||||
López N1, Torné A2, Franco A3, San-Martin M1, Viayna E4, Barrull C4, Perulero N4 | ||||
1 Medical Affairs, Sanofi Pasteur MSD, Madrid, Spain 2 Gynecologic Oncology Unit, Institut Clinic of Gynecology, Obstetrics and Neonatology (ICGON), Hospital Clínic-Institut d′Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine, University of Barcelona, Barcelona, Spain 3 Diagnostic Unit of Urology, Clinic Institute of Nephrology and Urology (ICNU) Hospital Clínic Barcelona, University of Barcelona, Barcelona, Spain 4 Health Economics and Outcomes Research, IMS Health, Barcelona, Spain | ||||
HPV2017 31st International papillomavirus conference, 2017, February 28 – March 4, Cape Town, South Africa |
||||
, Poster | ||||
, Spain | ||||
Abstract: http://hpv2017.org/Documents/HPV%202017%20Final%20Program%20SPIRAL.pdf | ||||
Condition | Year | Language | Analysis type | |
, Dermatology, Health economics, Immunology and Vaccination, Oncology | 2017 | English | , Burden of illness, Clinical setting: hospital, Clinical setting: Primary care, clinical setting: Secondary care, Epidemiological study, Literature Review, Survey research | |
Análisis de coste-efectividad de empagliflozina en pacientes con diabetes mellitus tipo 2 y enfermedad cardiovascular establecida en España [Analysis of cost-effectiveness of empagliflozin in patients with type 2 diabetes mellitus and cardiovascular disease established in Spain]. | ||||
Barrull C1, Massafrets M2, Planellas L1, Perulero N1 | ||||
1 RWI, QuintilesIMS, Barcelona 2 Market Access Department, Boehringer Ingelheim, Barcelona | ||||
XXXVII Jornadas de Economía de la Salud2017, 6 - 8 de septiembre, Barcelona, España |
||||
, Poster | ||||
, Spain | ||||
Abstract: http://www.aes.es/jornadas/en/ | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease, Diabetes, Health economics, Pricing and reimbursement | 2017 | Spanish | , Clinical setting: hospital, Clinical setting: Primary care, clinical setting: Secondary care, Cost effectiveness, Cost utility, Literature Review, Patient questionnaire, Randomised controlled trial | |
Impacto económico de las enfermedades asociadas al VPH en España: beneficio potencial de la vacuna nonavalente frente a la tetravalente [Economic impact of HPV-associated diseases in Spain: potential benefit of nonvalorent versus tetravalent vaccine]. | ||||
López N1, Torné A2, Franco A3, San-Martin M1, Viayna E4, Barrull C4 | ||||
1 Medical Affairs, MSD, Madrid, Spain 2 Gynecologic Oncology Unit, Institut Clinic of Gynecology, Obstetrics and Neonatology (ICGON), Hospital Clínic-Institut d′Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Faculty of Medicine, University of Barcelona, Barcelona, Spain 3 Diagnostic Unit of Urology, Clinic Institute of Nephrology and Urology (ICNU) Hospital Clínic Barcelona, University of Barcelona, Barcelona, Spain 4 Health Economics and Outcomes Research, IMS Health, Barcelona, Spain | ||||
XXXVII Jornadas de Economía de la Salud, 2017, 6 - 8 de septiembre, Barcelona, España |
||||
, Poster | ||||
, Spain | ||||
Abstract: http://www.aes.es/jornadas/en/ | ||||
Condition | Year | Language | Analysis type | |
, Dermatology, Health economics, Immunology and Vaccination, Oncology | 2017 | Spanish | , Burden of illness, Clinical setting: hospital, Clinical setting: Primary care, clinical setting: Secondary care, Literature Review, Survey research | |
Estimación de la carga epidemiológica de patologías asociadas a 9 genotipos del virus del papiloma humano en España: revisión de la literatura [Estimating the epidemiological burden of pathologies associated with 9 human papillomavirus genotypes in Spain: Literature review]. | ||||
Lopez N1, Viayna E2, Perulero N2, San-Martin M1 | ||||
1 Sanofi Pasteur-MSD 2 Quintiles IMS | ||||
Vacunas. 2017;18(2):36-42 |
||||
, Article | ||||
, Spain | ||||
Abstract: http://www.elsevier.es/es-revista-vacunas-72-avance-resumen-estimacion-carga-epidemiologica-patologias-asociadas-S1576988716300644?referer=buscador | ||||
Condition | Year | Language | Analysis type | |
, Dermatology, Health economics, Immunology and Vaccination, Oncology | 2017 | Spanish | , Burden of illness, Clinical setting: hospital, Clinical setting: Primary care, clinical setting: Secondary care, Literature Review | |
Carga epidemiológica y económica de las patologías asociadas al virus del papiloma humano en españa: revisión de la literatura [Epidemiological and economic burden of pathologies associated with human papillomavirus in Spain: literature review]. | ||||
Lopez N1, Viayna E2, Perulero N2, San-Martin M1 | ||||
1 Sanofi Pasteur-MSD 2 Quintiles IMS | ||||
XXXVII Jornadas de Economía de la Salud, 2017, 6 - 8 de septiembre, Barcelona, España |
||||
, Poster | ||||
, Spain | ||||
Abstract: http://www.aes.es/jornadas/en/ | ||||
Condition | Year | Language | Analysis type | |
, Dermatology, Health economics, Immunology and Vaccination, Oncology | 2017 | Spanish | , Burden of illness, Clinical setting: hospital, Clinical setting: Primary care, clinical setting: Secondary care, Literature Review | |
Revisión de modelos económicos de coste-efectividad/ coste-utilidad desarrollados con los nuevos agentes antivirales de acción directa para el tratamiento de pacientes con hepatitis c [Review of economic cost-effectiveness / cost-utility models developed with new direct-acting antiviral agents for the treatment of patients with hepatitis C]. | ||||
Planellas L1, Pascual N2, Solozabal M1, Rebollo P1, Puig-Junoy J2 | ||||
1 QuintilesIMS, RWI, Barcelona, Spain 2 CRES - Universitat Pompeu Fabra, Barcelona, Spain | ||||
XXXVII Jornadas de Economía de la Salud, 2017, 6 - 8 de septiembre, Barcelona, España |
||||
, Poster | ||||
, Spain | ||||
Abstract: http://www.aes.es/jornadas/es/#comunicaciones | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Infectious disease | 2017 | Spanish | , Cost effectiveness, Literature Review, Review | |
Determinants of the relationship between improved glucose control and modelled health outcomes in type 2 diabetes simulation models. | ||||
Foos V1, Lamotte M1, Altrabsheh E2, Sathananthan A2, McEwan P3 | ||||
1 QuintilesIMS, Zaventem, Belgium, 2 QuintilesIMS, London, United Kingdom, 3 Health Economics and Outcomes Research Ltd, Cardiff, United Kingdom | ||||
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual European Congress, 2017, November 4 - 8, Glasgow, Scotland |
||||
, Poster | ||||
, USA | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Health economics | 2017 | English | , Cost effectiveness | |
Exploration of run-time requirements in probabilistic sensitivity analysis utilizing a patient level based type 2 diabetes simulation model. | ||||
Foos V1, Lamotte M1, Sathananthan A2, Altrabsheh E2, McEwan P3 | ||||
1 QuintilesIMS, Zaventem, Belgium, 2 QuintilesIMS, London, United Kingdom, 3 Health Economics and Outcomes Research Ltd, Cardiff, United Kingdom | ||||
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 20th Annual European Congress, 2017, Nov 4 - 8, Glasgow, Scotland |
||||
, Poster | ||||
, USA | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Health economics | 2017 | English | , Cost effectiveness | |
BIOSIMILARS AND REFERENCE PRICE GROUPS IN GERMANY | ||||
Eheberg D1, Pointner J1, Antoni B1, Gossmann JA1, Batscheider A1 | ||||
1IMS Health, Munich, Germany | ||||
, Abstract | ||||
, Germany | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2016 | English | , Pricing & Reimbursement | |
USE OF REAL WORLD DATA IN IDENTIFYING RELEVANT COMPARATORS IN MEDICO ECONOMIC MODELS AT EU5 LEVEL: A CASE STUDY ON MULTIPLE MYELOMA | ||||
Jubert H, Kolahi C, Karusisi N, Mitrofan L | ||||
IMS Health France | ||||
19th ISPOR congress 2016 |
||||
, Abstract, Poster | ||||
, France, Germany, Italy, Spain, UK | ||||
Abstract: https://www.ispor.org/research_pdfs/54/pdffiles/PCN150.pdf | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Oncology | 2016 | English | , Clinical setting: hospital, Population Based Study, Real World Data, Retrospective database analysis | |
Estimated budget impact of adopting the affordable care act’s required smoking cessation coverage on united states healthcare payers. | ||||
Baker CL, Ferrufino CP, Bruno M, Kowal S | ||||
Advances in Therapy. 2016 November; 25:1-5 |
||||
, Manuscript in preparation | ||||
, USA | ||||
Abstract: http://link.springer.com/article/10.1007/s12325-016-0446-y | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2016 | English | , Budget impact, Cost analysis | |
A cost-effectiveness evaluation comparing originator follitropin alfa to the biosimilar for the treatment of infertility | ||||
Gizzo S1, Garcia-Velasco JA2, Heiman F3, Ripellino C3, Bühler K4 | ||||
1 Department of Woman and Child Health, University of Padua, Padua, Italy 2 Department of Obstetrics and Gynecology, Rey Juan Carlos University Madrid, Madrid, Spain 3 IMS Health Information Solutions Italy Srl, Milan, Italy 4 Centre for Gynaecology, Endocrinology, and Reproductive Medicine, Ulm and Stuttgart, Germany | ||||
Int J Womens Health |
||||
, Manuscript in preparation | ||||
, Germany, Italy, Spain, UK | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5153281/ | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Pregnancy | 2016 | English | , Cost effectiveness | |
The costs of managing genital warts in the UK by devolved nation: England, Scotland, Wales and Northern Ireland | ||||
Coles VA, Chapman R, Lanitis T, Carroll SM | ||||
Sanofi Pasteur MSD; Evidera | ||||
, Article | ||||
, UK | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Infectious disease | 2016 | English | , Retrospective database analysis | |
Health economic burden that different wound types impose on the UK's National Health Service. | ||||
Guest JF, Ayoub N, McIlwraith T, Uchegbu I, Gerrish A, Weidlich D, Vowden K, Vowden P | ||||
Catalyst Health Economics Consultants; Faculty of Life Sciences and Medicine, King's College; Bradford Teaching Hospitals NHS Foundation Trust and University of Bradford | ||||
, Article | ||||
, UK | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Injuries | 2016 | English | , Retrospective database analysis | |
Disease Control, Health Resource Use, Healthcare Costs, and Predictors in Gout Patients in the United States, the United Kingdom, Germany, and France: A Retrospective Analysis. | ||||
Morlock R, Chevalier P, Horne L, Nuevo J, Storgard C, Aiyer L, Hines DM, Ansolabehere X, Nyberg F. | ||||
Rheumatol Ther. 2016 Jun;3(1):53-75. |
||||
, Article | ||||
, France, Germany, UK, USA | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Health policy, Metabolic Disorders , Public Health | 2016 | English | , Retrospective cohort analysis | |
Budget impact of contrast media choice and contrast induced acute kidney injury in high-risk patients undergoing invasive coronary angiography with or without percutaneous coronary intervention from a us hospital perspective. | ||||
Todoran T, Goldfarb S, Pena CS, Ferrufino CP, Kowal S, De Francesco M, Lamotte M, King A | ||||
International Society for Pharmacoeconomics and Outcomes Research – 21st Annual International Meeting, 2016, May, Washington D.C. |
||||
, Abstract | ||||
, USA | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Nephrology | 2016 | English | , Budget impact | |
Coste del síndrome del intestino irritable con predominio de estreñimiento en España | ||||
Xavier Cortés1, Montse Roset2, Carmen Barrull2, Carolina Sais3, Anna Raya4 | ||||
1 Departamento Médico, Almirall S.A., Barcelona, España; 2 Health Economics & Outcomes Research, IMS Health, Barcelona, España; 3 IASIST, Barcelona, España; 4 Departamento de Marketing, Almirall S.A., Barcelona, España | ||||
PharmacoEcon Span Res Artic (2016) 13(1):1-8. |
||||
, Article | ||||
, Spain | ||||
Abstract: https://link.springer.com/article/10.1007/s40277-015-0048-0 | ||||
Condition | Year | Language | Analysis type | |
, Clinical practice, Gastrointestinal disorders, Health economics | 2016 | Spanish | , Burden of illness, Clinical setting: Primary care, Cost analysis, Retrospective database analysis | |
Impacto presupuestario del uso de un contraste isoosmolar frente a contrastes de baja osmolaridad en pacientes con alto riesgo de nefropatía inducida por contraste en el entorno hospitalario español | ||||
Eduardo Pinar1, José María Hernández2, Josepa Mauri3, Francisco Picó4, Rafael Ruiz5, Ángel Luis de Francisco6, Carmen Barrull7, Emilio Moreno8, Alexis Sampedro8, Felipe Hernández9 | ||||
1 Servicio de Hemodinámica, Servicio de Cardiología, Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar, Murcia, España; 2 Unidad de Hemodinámica, Hospital Virgen de la Victoria, Málaga, España; 3 Unitat d’Hemodinàmica i Cardiologia Intervencionista, Hospital Universitari Germans Trias i Pujol, Barcelona, España; 4 Unidad de Cardiología y Hemodinámica, Hospital Quirón, Murcia, España; 5 Servicio de Hemodinámica e Intervención Endovascular, Hospital Virgen Macarena, Sevilla, España; 6 Servicio de Nefrología, Hospital Universitario Marqués de Valdecilla, Santander, España; 7 Health Economics & Outcomes Research, IMS Health, Barcelona, España; 8 Departamento Médico, GE Healthcare, Madrid, España; 9 Servicio de Cardiología, Hospital Universitario Doce de Octubre, Madrid, España | ||||
PharmacoEcon Span Res Artic (2016) 13(1):17-24. |
||||
, Article | ||||
, Spain | ||||
Abstract: https://link.springer.com/article/10.1007%2Fs40277-015-0049-z | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease, Drug safety, Drug Utlization Study, Health economics | 2016 | Spanish | , Budget impact, Clinical setting: hospital | |
The Burden of Ulcerative Colitis and Crohn’s Disease in Spain | ||||
Cortés X1, Fernández-Salazar L2, Márquez L3, Ramos L4, Díaz Rubio C5, Planellas L6, Gasche D6 | ||||
1Gastroenterology Section, Internal Medicine of Hospital Universitario de Sagunto. University CEU Cardenal Herrera, Department of Medicine, Valencia; 2Department of Gastroenterology of Hospital Clínico Universitario de Valladolid; Department of Gastroenterology of Hospital del Mar de Barcelona; 4Department of Gastroenterology of Hospital Universitario de Canarias; 5Market Access Department, AbbVie; 6HEOR-RWE, IMS Health | ||||
Revista Española de la Economía de Salud (EDS). 2016;11(5):902-913 |
||||
, Article | ||||
, Spain | ||||
Abstract: http://www.economiadelasalud.com/Articulo.aspx?i=n5d018 | ||||
Condition | Year | Language | Analysis type | |
, Gastrointestinal disorders, Health economics, Immunology and Vaccination | 2016 | English | , Burden of illness, Clinical setting: hospital, Survey research | |
Análisis del impacto presupuestario de misoprostol en la maduración cervical e inducción del parto a término | ||||
De la Torre A1, Arjona Berral JA1, Gasche D2, Miñarro C2 | ||||
1Unidad de Gestión Clínica de Obstetricia y Ginecología, Hospital Universitario Reina Sofía de Córdoba, Córdoba, España; 2Health Economics & Outcomes Research Real-World Evidence Solutions, IMS Health, S.A., Madrid, España | ||||
Pharmacoecon Span Res Artic (2016) 13:141–147 |
||||
, Spain | ||||
Abstract: https://link.springer.com/article/10.1007/s40277-016-0060-z | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2016 | Spanish | , Budget impact, Clinical setting: hospital, Literature Review | |
The daily cost of ICU patients: A micro-costing study in 23 French Intensive Care Units. | ||||
Lefrant JY1, Garrigues B2, Pribil C3, Bardoulat I4, Courtial F4, Maurel F4, Bazin JÉ5; CRREA Study Group; AzuRea Group. | ||||
1Division anesthésie réanimation douleur urgences, faculté de médecine, université Montpellier 1, CHU de Nîmes, place du Professeur-Robert-Debré, 30029 Nîmes cedex 9, France. Electronic address: jean.yves.lefrant@chu-nimes.fr. 2Service de réanimation et de surveillances médico-chirurgicales polyvalentes, centre hospitalier du Pays d'Aix, Aix-en-Provence, France. 3Health Outcomes Department, GlaxoSmithKline, 100, route de Versailles, 78163 Marly-le-Roi cedex, France. 4IMS Health, Health Economics and Outcomes Research Department, Tour Ariane, 5-7, place de la Pyramide, 92088 La Défense cedex, France. 5Service anesthésie réanimation, CHU de Clermont-Ferrand, 1, place Lucile-Aubrac, 63003 Clermont-Ferrand cedex, France. | ||||
Anaesthesia Critical Care and Pain Medicine 2015 |
||||
, Article | ||||
, France | ||||
Abstract: https://www.ncbi.nlm.nih.gov/pubmed/25986476 | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2015 | English | , Cost analysis, Economic evaluation, Observational study | |
Can different primary care databases produce comparable estimates of burden of disease: results of a study exploring venous leg ulceration | ||||
Petherick ES, Pickett KE & Cullum NA | ||||
, Article | ||||
, UK | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2015 | English | , Retrospective database analysis | |
Clinical outcomes and cost-effectiveness of three alternative compression systems used in the management of venous leg ulcers | ||||
Guest JF, Gerrish A, Ayoub N, Vowden K & Vowden P | ||||
Catalyst | ||||
J Wound Care 24(7):300-10 |
||||
, Article | ||||
, UK | ||||
Abstract: http://www.catalyst-health.co.uk/wound-healing-11.html | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2015 | English | , Retrospective database analysis | |
An assessment of chemotherapy-induced nausea and vomiting direct costs in three EU countries. | ||||
Turini M1, Piovesana V1, Ruffo P1, Ripellino C2, Cataldo N2. | ||||
1 Helsinn S A., Lugano, Switzerland, 2 IMS Health Information Solutions Medical Research srl, Milan, Italy. | ||||
Drugs Context. 28;4:212285. |
||||
, Article | ||||
, France, Germany, Italy | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4544273/pdf/dic-4-212285.pdf | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Oncology | 2015 | English | , Survey research | |
A cost-effectiveness evaluation comparing biosimilar Bemfola to Gonal-f for the treatment of infertility in an Italian contest. | ||||
Ripellino C1, Visentin E1, Gizzo S2, Bühler K3 | ||||
1 IMS Health Information Solutions Medical Research S.r.l, Milan, Italy 2 University of Padua, padua, Italy 3 Centre for Gynaecology, Endocrinology and Reproductive Medicine, Ulm and Stuttgart, Germany | ||||
ISPOR Annual European Congress. Milan, Italy. |
||||
, Poster | ||||
, Italy | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Pregnancy | 2015 | English | , Cost analysis, Economic evaluation | |
Access to New Medicines in Public Drug Plans: Canada and Comparable Countries 2015 Annual Report | ||||
Millson B1, Thiele S1, Zhang Y1, Dobson-Belaire W1, Skinner B2 | ||||
1 IMS Health Canada Inc., 16720 Trans-Canada Highway, Kirkland, Quebec H9H 5M3 2 Innovative Medicines Canada, 55 Metcalfe Street, Suite 1220, Ottawa, Ontario K1P 6L5 | ||||
Innovative Medicines Canada Annual Report 2016 |
||||
, Report | ||||
, Canada | ||||
Abstract: http://innovativemedicines.ca/wp-content/uploads/2016/05/20160524_Access_to_Medicines_Report_EN_Web.pdf | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Health policy | 2015 | English | , Review | |
Health economic burden that wounds impose on the National Health Service in the UK | ||||
Guest JF, Ayoub N, McIlwraith T, Uchegbu I, Gerrish A, Weidlich D, Vowden K, Vowden P | ||||
Catalyst Health Economics Consultants, Northwood,; Bradford Teaching Hospitals NHS Foundation Trust and University of Bradford | ||||
, Article | ||||
, UK | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Injuries | 2015 | English | , Retrospective database analysis | |
A cost comparison of long-acting insulin analogs vs NPH insulin-based treatment in patients with type 2 diabetes using routinely collected primary care data from the UK | ||||
Idris I, Gordon J, Tilling C, Vora J | ||||
Division of Medical Sciences & Graduate Entry Medicine, University of Nottingham | ||||
, Article | ||||
, UK | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Health economics | 2015 | English | , Retrospective database analysis | |
Cost-Effectiveness Analysis of Delayed-Release Dimethyl Fumarate for The Treatment of Relapsing Remitting Multiple Sclerosis In Spain. | ||||
Gasche D1, Restovic G1, Casado V2, Ramírez-Boix P3, Martínez Lopez J3 | ||||
1IMS Health, Barcelona, Spain; 2Mataro Hospital, Mataro, Barcelona, Spain; 3Biogen, Madrid, Spain | ||||
Value in Health. Volume 18, Issue 7, November 2015, Page A755 |
||||
, Abstract | ||||
, Spain | ||||
Abstract: https://www.sciencedirect.com/science/article/pii/S1098301515050123?via%3Dihub | ||||
Condition | Year | Language | Analysis type | |
, Comparative Effectiveness & Health Technology Assessment, Health economics, Neurological disorders | 2015 | English | , Clinical setting: hospital, Cost effectiveness, Literature Review | |
Big data, advanced analytics and the transformation of healthcare delivery: Practical applications in healthcare research | ||||
Keja J1, Incardona F2, Blunt I3, Rigg J1 | ||||
1 Real-World Evidence Solutions & HEOR, IMS Health, London, UK 2 Italian Parliamentary Commission on Medical Errors, and Expert Evaluator, European Commission, Rome, Italy 3 The Nutfield Trust, London, UK | ||||
ISPOR 17th Annual European Congress, 8-12 November 2014, Amsterdam, The Netherlands |
||||
, Symposium | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2014 | English | , Real World Data | |
Relevance of indirect comparisons in the German early benefit assessment and in comparison to HTA processes in England, France and Scotland | ||||
Lebioda A1, Gasche D2, Dippel F-W3, Theobald K4, Plantör S1 | ||||
1 IMS Health,Munich, Germany 2 IMS Health, Barcelona, Spain 3 Sanofi-Aventis Deutschland GmbH, Berlin, Germany 4 Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany | ||||
Health Economics Review, 2014, 4(31) |
||||
, Article | ||||
, Germany | ||||
Abstract: doi:10.1186/s13561-014-0031-5 | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2014 | English | , Methodology | |
Evidence-based insights in oncology: The journey is only just beginning | ||||
Ghai C | ||||
RWE Solutions & HEOR, IMS Health, New York, USA | ||||
AccessPoint, 2014, May; 4(8): 14-20 |
||||
, Article | ||||
, USA | ||||
Abstract: http://issuu.com/ims_heor_publications/docs/ims_rwe_accesspoint_8_-_250514f_iss | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Oncology | 2014 | English | , Real World Evidence | |
Patient-reported outcomes assessment | ||||
Crawford B1, Luo N2 | ||||
1 Real World Evidence Solutions, Japan & APAC, IMS Health KK, Tokyo, Japan 2 Saw Swee Hock School of Public Health, National University of Singapore, Singapore | ||||
ISPOR 6th Asia-Pacific Conference, Beijing, China, 6-9 September, 2014 (short course) |
||||
, Workshop | ||||
Abstract: http://www.ispor.org/Event/Index/44 | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2014 | English | , Real World Evidence | |
Cost-effectiveness of asenapine in the treatment of patients with bipolar I disorder with mixed episodes in an Italian context. | ||||
Caresano C1, Di Sciascio G2, Fagiolini A3, Maina G4, Perugi G5, Ripellino C6, Vampini C7. | ||||
1 Department of Psychiatry, Lundbeck Italia S.p.A, Milan, Italy, 2 Department of Psychiatry, Policlinico Hospital, Bari, Italy, 3 Department of Molecular Medicine, University of Siena, Siena, Italy, 4 Department of Neurosciences, University of Torino, Turin, Italy, 5 Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, 6 Institute of Behavioural Sciences ‘‘G. De Lisio’’, Pisa, 7 CSD Medical Research S.R.L., Milan, Italy, 8 Department of Mental Health, Ospedale Civile Maggiore, Verona, Italy. | ||||
Adv Ther. 2014 Aug;31(8):873-90. doi: 10.1007/s12325-014-0139-3. Epub 2014 Jul 24 |
||||
, Article | ||||
, Italy | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/25055791 | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Mental health | 2014 | English | , Cost effectiveness | |
GOLD guidelines adherence impact on the NHS budget | ||||
Ripellino C, Guasconi A, Heiman F. | ||||
Cegedim Strategic Data Medical Research srl | ||||
Farmeconomia. 2014;Vol 15, No 1. |
||||
, Article | ||||
, Italy | ||||
Abstract: http://journals.edizioniseed.it/index.php/FE/article/view/887 | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Respiratory disease | 2014 | English | , Economic evaluation, Retrospective database analysis | |
Prevalence of smoking among patients treated in NHS hospitals in England in 2010/2011: a national audit. | ||||
Szatkowski L, Murray R, Hubbard R, Agrawal S, Huang Y & Britton J | ||||
University of Nottingham Division of Epidemiology and Public Health | ||||
Thorax. 2014 Nov 10. pii: thoraxjnl-2014-206285. doi: 10.1136/thoraxjnl-2014-206285 |
||||
, Article | ||||
, UK | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/25385425 | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Miscellaneous | 2014 | English | , Epidemiological study, Retrospective database analysis | |
Understanding the cost of hereditary angioedema in England. | ||||
Helbert M, Holbrook T, MacCulloch A & Mannan A | ||||
Manchester Royal Infirmary Immunology | ||||
The European Conference on Rare Diseases and Orphan Products (ECRD); 8th–10th May 2014; Berlin, Germany UK/CIN |
||||
, Poster | ||||
, UK | ||||
Abstract: http://www.rare-diseases.eu/wp-content/uploads/2013/08/27_t1.pdf | ||||
Condition | Year | Language | Analysis type | |
, Dermatology, Health economics | 2014 | English | , Retrospective database analysis | |
ASHP national survey of pharmacy practice in hospital settings: Prescribing and transcribing-2013 | ||||
Pedersen CA, Schneider PJ, Scheckelhoff DJ. | ||||
Confluence Health-Central Washington Hospital, Wenatchee, WA | ||||
Am J Health Syst Pharm 2014;71(11):924-942. |
||||
, Article | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/?term=ASHP+national+survey+of+pharmacy+practice+in+hospital+settings%3A+Prescribing+and+transcribing-2013. | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2014 | English | , Real World Evidence | |
National Health Spending In 2012: Rate Of Health Spending Growth Remained Low For The Fourth Consecutive Year | ||||
Martin AB, Hartman M, Whittle L, Catlin A, Team the NHEA | ||||
National Health Expenditure Accounts Team | ||||
Health Aff 2014;33(1):67-77. |
||||
, Article | ||||
Abstract: http://content.healthaffairs.org/content/33/1/67.full | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2014 | English | , Retrospective cohort analysis | |
Herpes Zoster-Related Health Care Resource Utilization in Cancer Patients in 5 European Countries | ||||
Gebremeskel B.G.1, Lopez-Gonzalez L.2, Patwardhan P.3, Chin J.4, Schwalm M.S.4, Acosta C.J.3,Margolis J.M.5 | ||||
VALUE IN HEALTH 17 ; A684 |
||||
, Abstract | ||||
, Belgium, France, Germany, Italy, Spain | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Immunology and Vaccination, Oncology | 2014 | English | , Cost of illness, Retrospective database analysis | |
The economic burden of dasatinib and nilotinib treatment failure in chronic myeloid leukemia (CML) patients: a real-world analysis | ||||
Pokras SM1, Divino V1, Ferrufino C1, Arnold RJA1, Huang H2 | ||||
1 IMS Health, Alexandria, USA 2 ARIAD Pharmaceuticals, Cambridge, USA | ||||
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 18th Annual International Meeting. May 20, 2013 |
||||
, Poster | ||||
, USA | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2013 | English | , Economic evaluation | |
Powering a new age of outcomes research | ||||
Keja J1, Bonzani I2 | ||||
1IMS Health, The Netherlands, 2IMS Health, London, UK | ||||
AccessPoint, May 2013; Vol 3(6); 18-22 |
||||
, Article | ||||
Abstract: http://issuu.com/ims_heor_publications/docs/rwe_accesspoint_6_-_080513f_epub | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Miscellaneous | 2013 | English | , Real World Evidence | |
Evolution of HTA and pharmaecoeconomic analyses in Latin America | ||||
Arnold R1 | ||||
1IMS Health, New York, USA | ||||
AccessPoint, May 2013; Vol 3(6); 44-49 |
||||
, Article | ||||
, Latin America | ||||
Abstract: http://issuu.com/ims_heor_publications/docs/rwe_accesspoint_6_-_080513f_epub | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Miscellaneous | 2013 | English | , Methodology | |
C-QUALITY: cost and quality-of-life pharmacoeconomic analysis of antidepressants in major depressive disorder in Italy. | ||||
Mencacci C1, Aguglia E2, Biggio G3, Cappellari L4, Di Sciascio G5, Fagiolini A6, Maina G7, Tortorella A8, Katz P9, Ripellino C9. | ||||
1 Department of Mental Health Fatebenefratelli Hospital, Milan, Italy, 2 Professor of Psychiatry, Department of Clinical and Molecular Biomedicine, University of Catania, 3 Department of Experimental Biology and Center of Excellence for the Neurobiology of Drug Dependence, University of Cagliari, Italy, 4 Department of Mental Health, Camposampiero Hospital, Padova, Italy, 5 Department of Psychiatry-Policlinico Hospital-Bari-Italy, 6 Department of Molecular Medicine University of Siena and Department of Mental Health, University of Siena Medical Center, 7 Department of Neurosciences, University of Torino, Italy, 8 Department of Mental Health, University of Naples, SUN, Italy, 9 CSD Medical Research Srl, Milan, Italy | ||||
Advances in Therapy. July 2013, Volume 30, Issue 7, pp 697-712. |
||||
, Article | ||||
, Italy | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/23929174 | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Mental health | 2013 | English | , Cost utility, Economic evaluation, Prospective study, Quality of life | |
Analisi farmaco-economica sui costi e la qualità di vita dei pazienti affetti da Disturbo Depressivo Maggiore (DDM) trattati con cura antidepressiva in Italia_ Pharmaco-economic analysis on the costs and quality of life of patients with Major Depressive Disorder (MDD) receiving antidepressant treatment in Italy. | ||||
Pegoraro V, Guasconi A, Mencacci C, Aguglia E, Biggio G, Cappellari L, Di Sciascio G, Fagiolini A, Maina G, Tortorella A, Ripellino C. | ||||
Center of Molecular and Genetic Epidemiology, Department of Environmental and Occupational Health, Università degli Studi di Milano and IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy | ||||
Congresso Nazionale SIHTA 2013, Bari |
||||
, Poster | ||||
, Italy | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Mental health, Neurological disorders | 2013 | Italian | , Cost analysis, Economic evaluation, Quality of life, Retrospective database analysis | |
C-QUALITY: Cost and Quality-of-Life Pharmacoeconomic Analysis of Antidepressants in Major Depressive Disorder in Italy. | ||||
Ripellino C, Heiman F, Katz P. | ||||
CSD Medical Research Milano | ||||
ISPOR Annual European Congress. 2013, Dublin Value in health |
||||
, Poster | ||||
, Italy | ||||
Abstract: http://www.valueinhealthjournal.com/article/S1098-3015(13)03318-4/abstract | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Mental health | 2013 | English | , Cost analysis, Quality of life | |
Audit of the effect of relative age on morbidity among children in The Health Improvement Network (THIN) UK data. | ||||
Johnson M, Mook P, Thompson M, Bourke A. | ||||
Cegedim | ||||
29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE) Montreal, Canada |
||||
, Poster | ||||
, UK | ||||
Abstract: http://csdmruk.cegedim.com/THINBibliography.pdf | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Miscellaneous | 2013 | English | , Retrospective database analysis | |
An evaluation of the THIN database in the OMOP Common Data Model for active drug safety surveillance. | ||||
Zhou X, Murugesan S, Bhullar H, Liu Q, Cai B, Wentworth C & Bate A | ||||
Cegedim | ||||
Drug Saf. 2013 Feb;36(2):119-34. doi: 10.1007/s40264-012-0009-3. |
||||
, Article | ||||
, UK | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/23329543 | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Methodology | 2013 | English | , Retrospective database analysis | |
Exploring the cost and burden of illness of hereditary angioedema in the UK. | ||||
Helbert M, Holbrook T, Drogon E & Mannan A | ||||
Adelphi | ||||
UK PIN Liverpool Liverpool, UK 2013 |
||||
, Poster | ||||
, UK | ||||
Abstract: http://csdmruk.cegedim.com/THINBibliography.pdf | ||||
Condition | Year | Language | Analysis type | |
, Dermatology, Health economics | 2013 | English | , Retrospective database analysis | |
Risk identification in Healthcare Records: comparison to epidemiological studies. | ||||
Edwards IR1, Karimi G1, Bergvall T1, Caster O1, Asiimwe A2, Star K1, Bhayat F3, Soriano-Gabarro M4, Thakrar B5, Thompson M6, Bate A7 & Norén GN1 | ||||
1 Uppsala Monitoring Centre, Uppsala, Sweden. 2 Eli Lilly UK, Surrey, United Kingdom. 3 Takeda (TGRD), London, United Kingdom. 4 Bayer Pharma AG, Berlin, Germany. 5 F Hoffmann-La Roche, Basel, Switzerland, 6 Cegedim Strategic Data Medical Research Ltd, London, United Kingdom. 7 Pfizer UK, Surrey, United Kingdom 6. Cegedim | ||||
29th International Conference on Pharma, coepidemiology and Therapeutic Risk Management (ICPE), Montreal, Canada |
||||
, Poster | ||||
, UK | ||||
Abstract: http://www.imi-protect.eu/documents/IREdwardsetalRiskidentificationinHealthcareRecordscomparisontoepidemiologicalstudiesICPEAug2.pdf | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Methodology | 2013 | English | , Retrospective database analysis | |
C-QUALITY: cost and quality-of-life pharmacoeconomic analysis of antidepressants used in major depressive disorder in the regional Italian settings of Veneto and Sardinia. | ||||
Mencacci C1, Aguglia E2, Biggio G3, Cappellari L4, Di Sciascio G5, Fagiolini A6, Maina G7, Tortorella A8, Katz P9, Ripellino C9. | ||||
1 Department of Mental Health, Fatebenefratelli Hospital, Milan 2 Department of Clinical and Molecular Biomedicine, University of Catania, Catania 3 Department of Experimental Biology and Center of Excellence for the Neurobiology of Drug Dependence, University of Cagliari, Calgiari 4 Department of Mental Health, Camposampiero Hospital, Padova 5 Department of Psychiatry, Policlinico Hospital, Bari 6 Department of Molecular Medicine, University of Siena and Department of Mental Health, University of Siena Medical Center, Siena 7 Department of Neurosciences, University of Torino, Torino 8 Department of Mental Health, University of Naples SUN, Naples 9 CSD Medical Research Srl, Milan, Italy | ||||
Clinicoecon Outcomes Res. 5:611-21 |
||||
, Article | ||||
, Italy | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/?term=C-QUALITY%3A+cost+and+quality-of-life+pharmacoeconomic+analysis+of+antidepressants+used+in+major+depressive+disorder+in+the+regional+Italian+settings+of+Veneto+and+Sardinia. | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Mental health | 2013 | English | , Cost utility, Economic evaluation, Quality of life | |
Less spending on prescription drug promotion | ||||
xxx | ||||
Massachusetts Institute of Technology | ||||
PharmacoEcon Outcomes News 2013;675(1):8-8 |
||||
, Abstract | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2013 | English | , Public Health | |
AstraZeneca's Real-World Bet | ||||
Upton J. | ||||
Pharmaceutical Executive | ||||
Pharmaceutical Executive |
||||
, Article | ||||
, UK | ||||
Abstract: http://www.pharmexec.com/pharmexec/article/articleDetail.jsp?id=761326 | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2012 | English | , Review | |
Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine. | ||||
Ikenberg R1, Hertel N2, Moore RA3, Obradovic M4, Baxter G5, Conway P5, Liedgens H4 | ||||
1 IMS Health GmbH & Co, Munich, Germany, 2 IMS Health, London, UK, 3 Oxford University, Oxford, UK, 4 Grünenthal GmbH, Aachen, Germany, 5 Grünenthal Ltd, Stokenchurch, UK | ||||
Journal of Medical Economics, 2012, 15(4): 1-13 |
||||
, Article | ||||
, UK | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/22364286 | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2012 | English | , Cost effectiveness | |
Cost-Effectiveness of Tapentadol in Severe Chronic Pain in Spain: A Cost Analysis of Data From RCTs | ||||
Obradovic M1, Ikenberg R2, Hertel N3, Antoñanzas F4, Gálvez R5, Liedgens H1 | ||||
1 Grünenthal GmbH, Aachen, Germany 2 IMS Health Economics and Outcomes Research, Munich, Germany 3 IMS Health Economics and Outcomes Research, London, UK 4 Department of Economics and Business, University of La Rioja, Logroño, Spain 5 Pain and Palliative Care Unit, University Hospital Virgen de las Nieves, Granada, Spain | ||||
Clinical Therapeutics/Volume 34, Number 4, 2012 |
||||
, Article | ||||
, Spain | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2012 | English | , Cost effectiveness | |
Learning from global trends in HTA | ||||
Nelson M1, Lee Chan W2 | ||||
1IMS Health, Alexandria, USA, 2IMS Health, San Francisco, USA | ||||
AccessPoint, Nov 2012; Vol 3(5); 42-49 |
||||
, Article | ||||
Abstract: http://www.imshealth.com/deployedfiles/imshealth/Global/Content/Services/Pharma%20Commercial%20Effectiveness/Health%20Economics%20_%20Outcomes%20Research/AccessPoint-5-281012%20F.pdf | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2012 | English | ||
Adapting global health economic models to emerging markets | ||||
Arnold R1 | ||||
1IMS Health, New York, USA | ||||
AccessPoint, Nov 2012; Vol 3(5); 30-36 |
||||
, Article | ||||
Abstract: http://www.imshealth.com/deployedfiles/imshealth/Global/Content/Services/Pharma%20Commercial%20Effectiveness/Health%20Economics%20_%20Outcomes%20Research/AccessPoint-5-281012%20F.pdf | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2012 | English | ||
Health economics analysis of pegfilgrastim in the prophylaxis of febrile neutropenia (FN) in Italy. | ||||
G. Rosti 1, M. Lebboroni 1, A. Cerchiari 2, P. Katz 3 | ||||
1 Ospedale Regionale Azienda Unità Locale Socio Sanitaria n°9 di Treviso, Oncologia Medica, Treviso, Italy 2 Amgen Dompè SpA, Health Economics, Milano, Italy 3 CSD Medical Research S.r.l, Pharmacoepidemiology & Health Economics, Milano, Italy | ||||
17th Congress of European Association of Hospital Pharmacists, |
||||
, Poster | ||||
, Italy | ||||
Abstract: http://ejhp.bmj.com/content/19/2/172.2 | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Hematology | 2012 | English | , Budget impact | |
COST-EFFECTIVENESS ANALYSIS OF DEPRESSION IN ITALY. | ||||
Katz P1, Mencacci C, Di Sciascio G, Ripellino C, Heiman F | ||||
1CSD Medical Research Milan | ||||
15th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Berlin, Germany |
||||
, Poster | ||||
, Italy | ||||
Abstract: http://www.ispor.org/E6E2C004-9FF1-4F7E-897E-BC292C74DF07/FinalDownload/DownloadId-24780E6AB48005853A097D13F4256DC1/E6E2C004-9FF1-4F7E-897E-BC292C74DF07/publications/value/valueinhealth_volume15_issue7.pdf | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Mental health, Neurological disorders | 2012 | English | , Cost effectiveness | |
Changing paradigms in the long‐term care market | ||||
Laryssa Wozniak, Mahmud Hassan, Dale Benner. | ||||
Confluence Health-Central Washington Hospital, Wenatchee, WA | ||||
Intl J of Pharm & Health Mrkt 2012;6(3):267-278. |
||||
, Article | ||||
Abstract: http://www.emeraldinsight.com/doi/abs/10.1108/17506121211259421 | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2012 | English | , Real World Evidence | |
The cost per day of intensive care units (ICU) in France : the CRRéa study. | ||||
Garrigues B1, Lefrant JY2, Bazin JE3, Bardoulat I4, Tagdichti K4, Courtial F4, Maurel F4, Pribil C5 | ||||
1 CH du Pays d'Aix, Aix-en6provence, France 2 CHU de Nîmes , Nîmes, France 3 CHRU de Clermont-Ferrand, Clermont-Ferrand, France 4 IMS Health, Puteaux, France 5 GSK France, Marly-le-Roi, France. | ||||
Abstract - Presentation PHP75 for the 14th European congress of Ispor 2011 |
||||
, Abstract, Poster | ||||
, France | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2011 | English | , Cost analysis, Economic evaluation, Prospective study | |
Resource utilisation related to catheter-associated urinary tract infections in Swedish spinal injury patients | ||||
Bruce S1, Löfroth E1, Knutsson B2, Börstell T2, Myrén KJ1. | ||||
1 IMS Consulting Group, Stockholm, Sweden. 2 AstraTech, Mölndal, Sweden. | ||||
ISPOR 14th Annual European Congress, 2010, 5-8 November, Madrid, Spain |
||||
, Poster | ||||
, Sweden | ||||
Abstract: http://www.ispor.org/congresses/Spain1111/Posters1.aspx | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Infectious disease, Urology | 2011 | English | , Burden of illness, Cost analysis, Epidemiological study, Retrospective database analysis | |
Resource utilisation related to urinary tract infections in Swedish self-catheterisation patients | ||||
Löfroth E1, Bruce S1, Knutsson B2, Börstell T2, Myrén KJ1. | ||||
1 IMS Consulting Group, Stockholm, Sweden. 2 AstraTech, Mölndal, Sweden. | ||||
ISPOR 14th Annual European Congress, 2010, 5-8 November, Madrid, Spain |
||||
, Poster | ||||
, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Infectious disease, Urology | 2011 | English | , Burden of illness, Cost analysis, Epidemiological study, Retrospective database analysis | |
Beyond Real-World Evidence | ||||
Badia X1, Bergström R2, Keja J3 | ||||
1 IMS Consulting Group, Barcelona, Spain; 2 EFPIA, Brussels, Belgium; 3 IMS Consulting Group, London, UK | ||||
ISPOR 14th Annual European Congress, 5th - 8th November, Madrid, Spain |
||||
, Symposium | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2011 | English | , Prospective study | |
Analisi di budget impact sull’utilizzo di pegfilgrastim nella profilassi della neutropenia febbrile in Italia. | ||||
Rosti G1, Lebboroni M1, Cerchiari A2, Katz P3. | ||||
1 Oncologia Medica, Ospedale Regionale, Azienda Unità Locale Socio Sanitaria n°9 di Treviso, 2 Amgen Dompè SpA, Italia, 3 CSD Medical Research Srl, Italia | ||||
Farmeconomia e percorsi terapeutici. 12(3). 119-127. |
||||
, Article | ||||
, Italy | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Oncology | 2011 | Italian | , Budget impact | |
Commercial importation of prescription drugs in the United States: short-run implications | ||||
Danzon PM, Johnson SJ, Long G, Furukawa MF | ||||
University of Rochester Medical Center, Rochester | ||||
J Health Polit Policy Law 2011;36(2):295-316. |
||||
, Article | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/?term=Commercial+importation+of+prescription+drugs+in+the+United+States%3A+short-run+implications. | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2011 | English | , Economic evaluation | |
Generalisability of The Health Improvement Network (THIN) database: demographics, chronic disease prevalence and mortality rates | ||||
Blak BT, Thompson M, Dattani H & Bourke A | ||||
Cegedim Strategic Data Medical Research Ltd, London, UK. | ||||
Inform Prim Care . 2011;19(4):251-5. doi: 10.14236/jhi.v19i4.820. |
||||
, Article | ||||
, UK | ||||
Abstract: https://pubmed.ncbi.nlm.nih.gov/22828580/ | ||||
Condition | Year | Language | Analysis type | |
, Database Validity and methodology, Health economics | 2011 | English | , Database Study | |
Impacto de la introducción de alitretinoína oral en los costes del eczema de las manos severo de origen profesional desde la perspectiva de las Mutuas de Accidentes de Trabajo y Enfermedades Profesionales en España. | ||||
Manuel Mascaró J, Quero Nasarre I, Lindner L, Prior M, Oliver J, Halbach R. | ||||
Manuel Mascaró J1, Quero Nasarre I2, Lindner L3, Prior M3, Oliver J4, Halbach R4. 1Servicio de Dermatología, Hospital Clínic de Barcelona. 2Servicio de Dermatología. MAZ de Zaragoza. 3IMS Health. 4Basilea Pharmaceuticals Iberia, S. L. | ||||
Rev. SEMST 2010; 5(1): 9-18 |
||||
, Article, Manuscript in preparation | ||||
, Spain | ||||
Abstract: http://dialnet.unirioja.es/servlet/articulo?codigo=3161177 | ||||
Condition | Year | Language | Analysis type | |
, Dermatology, Health economics | 2010 | Spanish | , Cost analysis, Cost consequence | |
Agreements with pharmaceutical industry: “Paying pay for results” | ||||
Badia X, Prior M. | ||||
Farm Hosp.2010;34(2):53–55. |
||||
, Article | ||||
, Spain | ||||
Abstract: http://www.sefh.es/fh/105_121v34n02pddf001.pdf | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2010 | Spanish | , Cost effectiveness | |
Regionalization of Market research. Why should it be evidence-based. | ||||
Badia X, Sabater J. | ||||
PM Farma 2010;XVII(105):54-55. |
||||
, Article | ||||
, Spain | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2010 | Spanish | , Cost analysis | |
Healthcare utilisation after platelet aggregation inhibitors. | ||||
Löfroth E, Myrén KJ, Bruce S. | ||||
IMS Health, Stockholm, Sweden. | ||||
ISPOR 13th Annual European Congress, 2010, 6-9 November, Prague, Czech Republic |
||||
, Poster | ||||
, Sweden | ||||
Abstract: http://www.ispor.org/congresses/Prague1110/posters2.aspx | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2010 | English | , Retrospective database analysis | |
Prevalence of affective disorders in South-West region of Sweden. | ||||
Löfroth E, Myrén KJ, Bruce S, Dahlberg E. | ||||
IMS Health, Stockholm, Sweden. | ||||
ISPOR 13th Annual European Congress, 2010, 6-9 November, Prague, Czech Republic |
||||
, Poster | ||||
, Nordic, Sweden | ||||
Abstract: http://www.ispor.org/congresses/Prague1110/posters3.aspx | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2010 | English | , Retrospective database analysis | |
Healthcare utilisation of major depressive disorder patients. | ||||
Myrén KJ, Löfroth E, Dahlberg E. | ||||
IMS Health, Stockholm, Sweden. | ||||
ISPOR 13th Annual European Congress, 2010, 6-9 November, Prague, Czech Republic |
||||
, Poster | ||||
, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2010 | English | , Retrospective database analysis | |
Cost impact of initiating pregabalin treatment in Swedish patients with generalized anxiety disorder. | ||||
Löfroth E1, Myrén KJ1, Sandelin R2. | ||||
1. IMS Health, Stockholm, Sweden. 2. Pfizer AB, Sollentuna, Sweden. | ||||
ISPOR 13th Annual European Congress, 2010, 6-9 November, Prague, Czech Republic |
||||
, Poster | ||||
, Sweden | ||||
Abstract: http://www.ispor.org/congresses/Prague1110/posters3.aspx | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2010 | English | , Retrospective database analysis | |
Cost impact from initiating pregabalin treatment in patients with refractory neuropathic pain. | ||||
Myrén KJ1, Löfroth E1, Sandelin R2. | ||||
1. IMS Health, Stockholm, Sweden. 2. Pfizer AB, Sollentuna, Sweden. | ||||
ISPOR 13th Annual European Congress, 2010, 6-9 November, Prague, Czech Republic |
||||
, Poster | ||||
, Sweden | ||||
Abstract: http://www.ispor.org/congresses/Prague1110/posters3.aspx | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2010 | English | , Retrospective database analysis | |
Assessment of the workload real time dedicated to each patient in intensive care units (ICU): preliminary results of the CRREA study | ||||
Garrigues B (1), Lefrant JY (2), Bazin JE (3), Probil C (4), Maurel F(5) | ||||
1. CH du Pays d'Aix, Aix en Provence, France 2. CHU de Nïmes, Nïmes, France 3. CHRU de Clermont-Ferrand, Clermont-Ferrand, France 4. GSK France, Marly-Le-Roi, France 5. IMS Health, Puteaux, France | ||||
ISPOR 13th Annula European Congress to be held 6-9 November 2010 at the Prague Congress Centre in Prague, Czech Republic |
||||
, Abstract, Poster | ||||
, France | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2010 | English | , Clinical setting: hospital, Cost analysis, Observational study, Prospective study | |
Quel est le temps réellement consacré à chaque patient en service de réanimation? résultats préliminaires de l'étude CRRéA | ||||
Lefrant JY (1), Bazin JE (2), Pribil C (3), Maurel F (4), Gariigues B (5) | ||||
1. CHU de Nîmes, Nîmes, France 2. CHRU de Clermont-Ferrand, Clermont Ferrand, France 3. GSK France, Marly-Le-Roi, France 4. IMS Health, Puteaux, France 5. CH du pays d’Aix, Aix-en-Provence, France | ||||
SFAR 2010, Congrès national d'anesthésie et de réanimation du 22 au 25 septembre 2010 - session Médecine d'urgence 2 |
||||
, Abstract, Oral presentation | ||||
, France | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2010 | French | , Cost analysis, Observational study | |
Cost-effectiveness of tapentadol prolonged-release (PR) compared to oxycodone and morphine in patients with chronic moderate to severe non-cancer pain in Sweden | ||||
Hertel N1, Ikenberg R1, Fricke FU12, Liedgens H3 | ||||
1IMS Health, Nuremberg, Germany 2Georg Simon Ohm University of Applied Sciences, Nuremberg, Germany 3Gruenenthal GmbH, Aachen, Germany | ||||
ISPOR November 6-9, 2010 Prague, Czech Republic |
||||
, Abstract | ||||
, Nordic, Sweden | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Musculoskeletal disease | 2010 | English | , Cost benefit | |
A cost-minimization analysis of dexmedetomidine compared with midazolam for long-term sedation in the intensive care unit* | ||||
Dasta JF, Kane-Gill SL, Pencina M, et al | ||||
University of Miami, Florida | ||||
Critical Care Medicine 2010;38(2):497-503 |
||||
, Abstract | ||||
Abstract: http://journals.lww.com/ccmjournal/Abstract/2010/02000/A_cost_minimization_analysis_of_dexmedetomidine.20.aspx | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2010 | English | , Cost minimization | |
Characterizing Markets for Biopharmaceutical Innovations: Do Biologics Differ from Small Molecules? | ||||
Trusheim MR, Aitken ML, Berndt ER. | ||||
Massachusetts Institute of Technology | ||||
Forum for Health Economics & Policy. Jul 2010; 13(1) 1558-9544. |
||||
, Book | ||||
Abstract: http://www.degruyter.com/dg/viewarticle/j$002ffhep.2010.13.1$002ffhep.2010.13.1.1200$002ffhep.2010.13.1.1200.xml | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2010 | English | , Public Health | |
Assessment of the workload real time dedicated to each patient in intensive care units (icu): preliminary results of the crréa study. | ||||
Garrigues B1, Lefrant JY2, Bazin JE3, Pribil C4, Maurel F5 | ||||
1 CH du pays d’Aix, Aix-en-Provence, France 2 CHU de Nîmes, Nîmes, France 3 CHRU de Clermont-Ferrand, Clermont Ferrand, France 4 GSK France, Marly-Le-Roi, France 5 IMS Health, Puteaux, France | ||||
ISPOR 13th Annual European Congress, 2010, 6-9 November, Prague, Czech Republic |
||||
, Poster | ||||
, France | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2010 | English | , Clinical setting: hospital, Cost effectiveness, Observational study, Prospective study | |
Using Early Economic Modelling to inform strategic pricing and clinical study design | ||||
Lloyd A1, Chambers M2, Caputo J1 | ||||
1 IMS Health, London, UK 2 GlaxoSmithKline, Uxbridge, UK | ||||
ISPOR 12th Annual European Congress, Paris France 24-27th October 2009 |
||||
, Workshop | ||||
, UK | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2009 | English | , Workshop | |
Verbrauch von Erythropoese-stimulierenden Faktoren in der Therapie der renalen Anämie - eine „real life“- Analyse der Versorgungssituation in Deutschland [Consumption of erythropoietin-stimulating factors in the renal anaemia therapy - a "real life"-analysis of the German medical treatment situation] | ||||
Schöffski O1, Müller H-J2, Kostev K3, Claus V4 | ||||
1 University Erlangen-Nuremberg, Nuremberg, Germany 2 Med. Klinik III Klinikum Fulda gAG, Fulda, Germany 3 IMS Health, Frankfurt, Germany 4 IMS Health, Munich, Germany | ||||
Congress for nephrology, Göttingen, Germany, 26-29 September 2009 |
||||
, Abstract, Poster | ||||
, Germany | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Hematology, Nephrology | 2009 | German | , Retrospective database analysis | |
[Coste-efectividad de la identificación genética en pacientes en tratamiento con acenocumarol] Genotyping in patients in treatment with acenocumarol cost-effectiveness. | ||||
Lindner L, Lara N, Tàssies D, Tejedor D, Jofre-Monseny L | ||||
Lindner L1, Lara N1, Tàssies D2, Tejedor D3, Jofre-Monseny L3. 1Health Economics & Outcomes Research - IMS Health; 2Servicio de Hemoterapia y Hemostasia.Hospital Clínic Barcelona. 3 Progenika Biopharma S.A | ||||
, Article, Manuscript in preparation | ||||
, Spain | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Hematology | 2009 | Spanish | , Cost effectiveness | |
Publication trends of budget impact analyses over the past six years. | ||||
Pathak P, Kowal-Podmore S, Munakata J | ||||
ISPOR 14th International Meeting |
||||
, Poster | ||||
, USA | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2009 | English | , Literature Review | |
Complex Attention-Deficit/Hyperactivity Disorder: Patient Characteristics, Health Care Utilization And Costs In A Retrospective Observational Claims Study | ||||
Hess G1, Sasane R2, Hill J1, Hodgkins P2, Shah MR1 | ||||
1IMS Health, former SDI Health, Plymouth Meeting, PA, USA, 2Shire Pharmaceuticals, Wayne, PA, USA | ||||
Value in Health Volume 12, Issue 7 , Page A361, October 2009 |
||||
, Article | ||||
Abstract: http://www.valueinhealthjournal.com/article/S1098-3015(10)74773-2 | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Pediatrics, Pricing and reimbursement | 2009 | English | , Cost analysis, Cost utility, Observational study | |
The importance of clinical variables in comparative analyses using propensity-score matching: the case of ESA costs for the treatment of chemotherapy-induced anaemia. | ||||
Polsky D1, Eremina D2, Hess G12, Hill J2, Hulnick S2, Roumm A2, Whyte JL3, Kallich J3 | ||||
1University of Pennsylvania, Philadelphia, PA, USA, 2IMS Health (Former SDI Health),Plymouth Meeting, PA, USA, 3Amgen Inc., Thousand Oaks, California, USA | ||||
Pharmacoeconomics. 2009;27(9):755-65 |
||||
, Article | ||||
Abstract: http://link.springer.com/article/10.2165%2F11313860-000000000-00000 | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Hematology | 2009 | English | , Cost analysis, Cost effectiveness, Quality of life | |
Cost-effectiveness analysis of smoking cessation pharmacotherapies in Australia | ||||
Bhatti T, Makino K, Guarnieri C, Gordois A, Cotter T, Perez D, Bishop J, Glass P | ||||
ISPOR 3rd Asia-Pacific Conference, Seoul, Korea, September 2008 |
||||
, Poster | ||||
, Australia | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2008 | English | , Cost effectiveness | |
Eficiency and drugs: Review of Guidelines for Economic Evaluation | ||||
Del Llano J, Pinto JL, Abellán JM, Barbieri M, Polanco C | ||||
La Cuarta Garantía. Sanofi-aventis, Barcelona (2008). ISBN: 978-84-691-2988-3 |
||||
, Book | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2008 | Spanish | , Economic evaluation | |
Modelo de impacto presupuestario de la administración de darbepoetina alfa cada 3 semanas comparado con la administración de epoetina alfa y epoetina beta 3 veces por semana y semanalmente en pacientes con anemia inducida por quimioterapia [Budget impact model of darbepoetin alfa administered once every three weeks relative to epoetin alfa and beta administered three times per week or weekly in patients with chemotherapy induced anaemia] | ||||
Pérez-Alcántara F1, Badia Llach X1, Riera Febrer M1, Vieta Salomó A1, Arocho R2 | ||||
1IMSHealth®; 2Amgen S.A. | ||||
Revista Española de Economía de la Salud 2008; 7(1):41-48 |
||||
, Article | ||||
, Spain | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2008 | Spanish | , Cost consequence | |
Economic assessment of controlled-release Oxycodone for the treatment of chronic pain | ||||
Gálvez Mateos R, Camps Herrero C, Lara Suriñach N, Polanco Sánchez C | ||||
Rev Esp Econ Salud 2008;7(4):157-164 |
||||
, Article | ||||
, Spain | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2008 | Spanish | , Economic evaluation | |
Impacto sociosanitario en pacientes con enfermedades raras (estudio ERES) [Sociosanitary impact on patients with rare diseases (ERES study)] | ||||
Avellaneda Fernández A1,2, Layola M3, Izquierdo Martínez M1,4, Guilera M3, Badia Llach X3, Ramón JR1 | ||||
1Instituto de Investigación de Enfermedades Raras (IIER). Instituto de Salud Carlos III. Madrid. 2Centro Sanitario Los Cármenes. Comunidad de Madrid. Madrid. 3Grupo Health Outcomes Research Europe (Grupo HOR-Europe). 4Servicio de Análisis e Intervención en Salud Pública. Dirección General de Salud Pública y Alimentación. Comunidad de Madrid. Madrid. España. | ||||
Medicina Clinica 2007;129(17):646-51 |
||||
, Article | ||||
, Spain | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2008 | Spanish | , Market impact | |
Global and Spanish Pharmaceuticals market trends | ||||
Prior M | ||||
The 28th days on Health economics: economics, behaviour and health, Salamanca 28-30 may 2008 |
||||
, Oral presentation | ||||
, Spain | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2008 | Spanish | ||
Retos en la evaluación económica de productos oncológicos [Challenges in economic evaluation of oncological products] | ||||
Badia X1 | ||||
1Health Economics and Outcomes Research, IMS Health, Barcelona, Spain, | ||||
Summer School of pharmacoeconomics: Economic evaluation of health intervention 2008 May 18-19, Granada, Spain |
||||
, Oral presentation | ||||
, Spain | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2008 | Spanish | , Economic evaluation | |
Regional market access inequalities for new oncology drugs in Spain | ||||
Vieta A1, Gimenez E1, Badia X1 | ||||
1Health Economics and Outcomes Research, IMS Health, Barcelona, Spain, | ||||
ISPOR 11th Annual European Congress 2008 November 8-11, Athens, Greece |
||||
, Oral presentation | ||||
, Spain | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2008 | English | ||
Pharmabetriebslehre [Business operations in the pharmaceutical industry] | ||||
Schöffski O1, Fricke F-U2, Guminski W3 (ed.) | ||||
1 University Erlangen-Nuremberg, Germany 2 IMS Health, Nuremberg, Germany 3 TNS Healthcare, Munich, Germany | ||||
Berlin-Heidelberg, Springer, Second edition |
||||
, Book | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2008 | German | , Methodology | |
Die pharmazeutische Industrie und der Arzneimittelmarkt [Pharmaceutical industry and drug market] | ||||
Fricke F-U1, Schöffski O2 | ||||
1 IMS Health, Nuremberg, Germany 2 University Erlangen-Nuremberg, Germany | ||||
Schöffski O, Fricke F-U, Guminski W (ed.). Pharmabetriebslehre, Berlin-Heidelberg, Springer, 2008, 23-46 |
||||
, Book chapter | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2008 | German | , Methodology | |
Pharmacotherapy evaluation: Drugs that assist smoking cessation | ||||
Perez D, Cotter T, Makino K, Bhatti T, Gordois A, Guarnieri C, Lewis S, Glass P, Bishop J | ||||
Sydney: Cancer Institute NSW |
||||
, Report | ||||
, Australia | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2008 | English | , Economic evaluation | |
Health economics review of bowel cancer in Australia | ||||
Bishop J, Glass P, Tracey E, Hardy M, Warner K, Makino K, Gordois A, Wilson J, Guarnieri C, Feng J, Sartori L | ||||
NSW Cancer Institute, Sydney |
||||
, Review | ||||
, Australia | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2008 | English | , Cost effectiveness | |
Cost-effectiveness of strong opioids focussing on the long-term effects of opioid-related fractures: a model approach. | ||||
Hass B1, Lungershausen J1, Hertel N1, Kotowa W1, Poulsen Nautrup B2, Liedgens H3 | ||||
1 IMS Health, Nuremberg, Germany 2 EAH-Consulting, Juelich, Germany 3 Gruenenthal GmbH, Aachen, Germany | ||||
The European journal of health economics, 21. Dezember 2008 |
||||
, Online article | ||||
, Germany | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Musculoskeletal disease | 2008 | English | , Cost effectiveness | |
Estimated costs associated with different fracture risks related to opioid treatment in Germany | ||||
Kotowa W1, Völkl M1, Hass B1, Poulsen Nautrup B2 | ||||
1 IMS Health, Nuremberg, Germany 2 EAH Consulting, Juelich, Northrhine Westf | ||||
ISPOR 12th Annual International Meeting 2007, May 19-23, Arlington, VA, USA |
||||
, Abstract, Oral presentation | ||||
, Germany | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2007 | English | , Cost effectiveness | |
From evidence-based medicine to health outcomes research:an approach to reality | ||||
Badia X, Lizán L. | ||||
Rev Esp Econ Salud 2007;6(1):42-44 |
||||
, Manuscript in preparation | ||||
, Spain | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2007 | Spanish | , Methodology | |
Economic evaluations in pricing and reimbursement process of pharmaceutical products in Europe | ||||
Vieta A, Lara N, Badia X | ||||
XXVII Jornadas de Economía de la Salud (AES). La Coruña 6-8 June |
||||
, Oral presentation | ||||
, Europe | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2007 | Spanish | , Pricing & Reimbursement | |
A cross-sectional validation of the mini-HIV questionnaire | ||||
Pedrol E, Ortega E, Sanz J, Suárez-Lozano I, Perulero N, García Pulgar MS, Escayola R | ||||
, Poster | ||||
, Spain | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2007 | English | , Quality of life | |
The impact of different resource cost definitions on results, interpretations, and comparability of health economic studies | ||||
Tunis SL1, Pelletier EM2, St. Charles M1, McEwan P3. | ||||
1IMS Health, Noblesville, IN, USA, 2IMS Health, Watertown, MA, USA, 3Cardiff Medicentre, University Hospital of Wales, Cardiff, UK | ||||
ISPOR 10th Annual European Meeting, 2007, October, Dublin, Ireland |
||||
, Workshop | ||||
, USA | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Methodology | 2007 | English | , Methodology, Retrospective database analysis | |
European databases and retrospective database analysis | ||||
Elise Pelletier; Erik Spaepen | ||||
ISPOR 2007 10th Annual European Congress |
||||
, Europe | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2007 | English | , Review | |
Der gesundheitspolitische Nutzen von Evaluationsstudien [The health-political benefit of evaluation-surveys] | ||||
Fricke FU | ||||
IMS Health, Nuremberg, Germany | ||||
Schoeffski O, v. d. Schulenburg JM (ed.): Gesundheitsökonomische Evaluationen, 3. vollständig überarbeitete Auflage, Berlin-Heidelberg, Springer, 2007, 509-534 |
||||
, Book chapter | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2007 | German | , Pricing & Reimbursement | |
Field Research | ||||
Pirk O1, Claes C2, Schöffski O2 | ||||
1 IMS Health, Nuremberg, Germany 2 Forschungsstelle für Gesundheitsökonomie und Gesundheitssystemforschung, Universität Hannover | ||||
Schoeffski O, v. d. Schulenburg JM (ed.): Gesundheitsökonomische Evaluationen, 3. vollständig überarbeitet Auflage, Berlin-Heidelberg, Springer, 2007, 201-260 |
||||
, Book chapter | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2007 | German | ||
The spectrum OF health care costs associated WITH herpes zoster: acute pain vs. postherpetic neuralgia | ||||
Hawkins K, White R, Dworkin R, O'connor A, Baser O | ||||
ISPOR 12th Annual International Meeting, May 19-23, 2007 |
||||
, Poster | ||||
, USA | ||||
Abstract: http://www.ispor.org/research_study_digest/details.asp | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2007 | English | ||
Patient transfer decrease and health insurance costs savings associated with telemedicine consultation. Example of the telemedicine network of “midi-pyrénées” (RTR) | ||||
LARENG L; SALVODELLI M; BILLON S; BOURGUIGNON S; LECLERCQ C. | ||||
ISPOR 2007 10th Annual European Congress |
||||
Condition | Year | Language | Analysis type | |
, Health economics | 2007 | English | ||
Conjoint analysis a technique to develop a questionnaire of treatment preferences in patients with lung cancer | ||||
Perulero N, Cardenal F, Garcia R, Juan O, Vázquez S, Barneto I, Varela C | ||||
, Poster | ||||
, Spain | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2007 | English | , Quality of life | |
Patients with myelodysplastic syndromes (MDS) challenge transfusion resources now and in the future | ||||
Plesnila Frank C, Rottenkolber D, Berger K | ||||
ISPOR 2007 10th Annual European Congress |
||||
, Germany | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2007 | English | ||
Evaluación económica de medicamentos biotecnológicos: retos y oportunidades [Economic Evaluation of biotechnological drugs: challenge and opportunities] | ||||
Badia Llach X, Polanco Sánchez C | ||||
Rev Esp Econ Salud 2007;6(6):352-7 |
||||
, Article | ||||
, Spain | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2007 | Spanish | , Economic evaluation | |
Is the regulation of the pharmaceutical market justified? | ||||
Vieta A | ||||
Rev Esp Econ Salud 2007;6(5):278-81 |
||||
, Article | ||||
, Spain | ||||
Abstract: http://www.economiadelasalud.com/Ediciones/65/08_pdf/regulation.pdf | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2007 | Spanish | ||
The cost of zoster and post-herpetic neuralgia treatment in France. | ||||
Loock J, Le Pen C, Baptiste C, Bloch K, Valentin E, Bruxelle J, Berrut G, Gallais JL, Stahl JP | ||||
ISPOR ISPOR 2007 10th Annual European Congress |
||||
, Abstract, Oral presentation | ||||
, France | ||||
Condition | Year | Language | Analysis type | |
, Dermatology, Health economics | 2007 | English | , Burden of illness | |
The relative cost-effectiveness of the fentanyl HCL patient-activated transdermal system (ITS) in acute post-operative pain management (POPM) in Greece. | ||||
Yfantopoulos I, Papanicolaou S, Papagiannopoulou V, Van Bellinghen LA, Annemans L | ||||
ISPOR 10th Annual European Congress, 2007, October 20-23, Dublin, Ireland ISPOR 2007 10th Annual European Congress |
||||
, Abstract | ||||
, Belgium, Greece | ||||
Condition | Year | Language | Analysis type | |
, Clinical practice, Health economics | 2007 | English | , Cost effectiveness | |
The impact of different resource cost definitions on results, interpretations, and comparability of health economic studies. | ||||
Tunis SL1, Pelletier EM1, St. Charles M1, McEwan P2 | ||||
1IMS Health, Inc., Watertown, MA, USA, 2 | ||||
International Society of Pharmacoeconomics and Outcomes Research (ISPOR) 10th Annual European Meeting, Dublin, Ireland, October 2007 |
||||
, Workshop | ||||
, USA | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Methodology, Miscellaneous | 2007 | English | , Retrospective database analysis | |
The cost-effectiveness of bisphosphonates in postmenopausal women based on individual long-term fracture risks. | ||||
Van Staa TP, Kanis JA, Geusens P, Boonen A, Leufkens HG & Cooper C | ||||
Utrecht University, Utrecht, The Netherlands | ||||
Value Health. 2007 Sep-Oct;10(5):348-57. |
||||
, Abstract, Article | ||||
, UK | ||||
Abstract: http://www.ncbi.nlm.nih.gov/pubmed/17888099 | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Womens Health | 2007 | English | , Retrospective database analysis | |
EL NUEVO PACIENTE: Los retos de la información sobre salud y medicamentos [The new patient, Information challenges on health and drugs] | ||||
Badia X, Valentín C | ||||
Madrid: MSD y Defensor del Paciente de la Comunidad de Madrid; 1st ed. Madrid 2006:13-58 |
||||
, Book chapter | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2006 | Spanish | ||
Use of EQ-5D questionnaire in economic evaluations | ||||
Betegón L,. Lara N, Badia X. | ||||
XXVII Jornadas de Economía de la Salud (AES). La Coruña 6-8 June |
||||
, Poster | ||||
, Spain | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2006 | Spanish | , Economic evaluation | |
Carer's perspective ON the valuation OF schizophrenia-related health states USING the assessment OF quality OF life questionnaire AND the EQ5D | ||||
Adams J, Le Reun C, Crowley S, Eggleston A | ||||
, Oral presentation | ||||
, Australia | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2006 | English | , Quality of life | |
Review of the use of the EQ5D in cost-utility analysis. | ||||
Betegón L, Badia X. | ||||
EuroQol Group Scientific Meeting 2006, Barcelona (Spain) 14-15 September |
||||
, Oral presentation | ||||
, Spain | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2006 | English | , Review | |
Review of the use of the Proxy version of the EQ-5D. | ||||
Lara N, Badia X. | ||||
EuroQol Group Scientific Meeting 2006, Barcelona (Spain) 14-15 September |
||||
, Oral presentation | ||||
, Spain | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2006 | English | , Review | |
Towards a better QALY model. | ||||
Abellán-Perpiñán J.M., Pinto-Prades J.L., Méndez-Martínez I, Badia Llach X. | ||||
Health Econ 2006;15:665-76 |
||||
, Manuscript in preparation | ||||
, Spain | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2006 | English | , Quality of life | |
When the direct to patient information in health and prescription drugs is already a fact through Internet. | ||||
Badia Llach X, Alonso-Rodríguez Piedra N. | ||||
Rev Esp Econ Salud 2006;5(5):272-5 |
||||
, Manuscript in preparation | ||||
, Spain | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2006 | English | ||
The new patient: the challenges of health and drugs information. | ||||
Badia X, Valentín C. | ||||
H.O.R. Europe, a unit of IMS | ||||
Madrid: MSD y Defensor del Paciente de la Comunidad de Madrid; 1st ed Merck Sharp & Dohme de España S.A, Madrid 2006;13-58 |
||||
, Manuscript in preparation | ||||
, Spain | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2006 | English | , Review | |
Visados de inspección: ¿garantía del uso adecuado de los medicamentos o medida de control del gasto? | ||||
Gutiérrez Nicuesa L, Magaz Marqués S, Badia Llach X. | ||||
Aten Prim;37(5):278-86 |
||||
, Manuscript in preparation | ||||
, Spain | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2006 | Spanish | ||
The Role of Pharmacoeconomics in US Managed Care Formulary Decisions: A Case Study | ||||
Minshall M | ||||
Pharma Pricing & Reimbursement, February 2007, pp46-50 |
||||
, Manuscript in preparation | ||||
, USA | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2006 | English | ||
Assessment of the economic value of the INTERCEPT Blood System in Belgium. | ||||
Moeremans K; Annemans L. | ||||
Transfusion Medicine, 2006; 16:17-30 |
||||
, Manuscript in preparation | ||||
, Belgium | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2006 | English | ||
Is it efficient to inform the patient about the new drugs? An economic model for Spain. | ||||
Badia X. | ||||
Forum on ""New challenges for the patients"", Madrid (Spain) 25 October |
||||
, Oral presentation | ||||
, Spain | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2006 | English | ||
Socioeconomic perspective of patient information. | ||||
Badia X. | ||||
Health Law Congress, Madrid (Spain) 19-20 October |
||||
, Oral presentation | ||||
, Spain | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2006 | English | ||
Health outcomes research: economic evaluation of pain. | ||||
Badia X. | ||||
VI expert meeting on socioeconomic issues of pain. Salamanca (Spain) 25 September |
||||
, Oral presentation | ||||
, Spain | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2006 | English | ||
Economic evaluation in Spain: current situation. | ||||
Badia X. | ||||
VI Jornada de Seminarios. Health Economics (Revista Española de Economía de la Salud, IESE, Fundamed), Madrid (Spain) 26 October |
||||
, Oral presentation | ||||
, Spain | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2006 | English | ||
Health-related quality of life in Outcomes Research. | ||||
Badia X. | ||||
VIII Jornadas Conjuntas de las Áreas 9 y 10 de Atención Primaria. The expectations and the achievements: we measure what we do or we do what we measure?, Getafe (Spain) 11 May |
||||
, Oral presentation | ||||
, Spain | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2006 | English | ||
Patient-Reported Outcomes (PRO). | ||||
Badia X. | ||||
XXIV Congreso de la Sociedad Española de Calidad Asistencial (Spanish Society of Quality in Assitance), Toledo (Spain) 24-27 October |
||||
, Oral presentation | ||||
, Spain | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2006 | English | ||
Extension and implications of Health Outcomes Research(HOR). | ||||
Badia X. | ||||
XXIV Congreso of the Sociedad Española de Calidad Asistencial (Spanish Society of Quality in Assitance), Toledo (Spain) 24-27 October |
||||
, Oral presentation | ||||
, Spain | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2006 | English | ||
Premature mortality associated to obesity in Spain: Adjusted Life Years. | ||||
Betegón L, Oliva J, Echevarria A, Badia X. | ||||
XXVI Jornadas de Economía de la Salud (Spanish Association on Health Economy, AES), Toledo (Spain) 23-26 May |
||||
, Oral presentation | ||||
, Spain | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2006 | English | ||
Recent policy initiatives in the Australian national reimbursement system that have reduced cost dramatically | ||||
Peter Davey. | ||||
ISPOR 11th Annual International Meeting ISPOR 11th International Meeting, 20-24 May 2006 Philadelphia, Pennsylvania, USA. Podium presentation. |
||||
, Oral presentation | ||||
, Australia | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Health policy | 2006 | English | , Pricing & Reimbursement | |
Assessing quality of life of rare diseases patients in Spain. ERES STUDY. | ||||
Badia X, Layola M, Pérez P, Avellaneda A, Izquierdo M. | ||||
13th Annual Conference of the International Society for Quality of Life Research (ISOQOL), Lisbon (Portugal) 11-14 October |
||||
, Poster | ||||
, Spain | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2006 | English | ||
Economic advantages and time savings of using oxaliplatin concentrated solution versus osaliplatin lyophilised powder for infusion | ||||
Favier B, Spath HM, Anhoury P, Pacull A | ||||
, Poster | ||||
, France | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2006 | English | ||
Validation of the patient’s attitudes and perceptions towards HAART questionnaire. | ||||
Fumaz C, Knobel H, Segador A, Lorenzo A, González J, García Pulgar M, Badia X, Perulero N. | ||||
, Poster | ||||
, Spain | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2006 | English | ||
Patients and physicians perceptions towards subcutaneous treatment. | ||||
Knobel H, Fumaz CR, Segador A, Lorenzo A, González J, García Pulgar M, Perulero N. | ||||
8th International Congress on Drug Therapy in HIV Infection, Glasgow (UK) 12-16 November |
||||
, Poster | ||||
, Spain | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2006 | English | ||
Estimating utility in rotavirus gastroenteritis in children under five in the UK | ||||
Martin A, Cotrell S | ||||
, Poster | ||||
, UK | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2006 | English | ||
An observational health-economic analysis of the treatment of patients with voriconazole in a real-life setting | ||||
Van Campenhout H, De Mees V, Marbaix S, Annemans L | ||||
, Poster | ||||
, Belgium | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2006 | English | ||
Auswirkungen der Gesundheitsökonomie in Industrie und Politik [Effects of Health Economy in Industry and Politics] | ||||
Fricke F-U | ||||
IMS Health, Nuremberg, Germany | ||||
Daumann F. et al.: Wettbewerb und Gesundheitswesen: Konzeption und Felder ordnungsökonomischen Denkens, Budapest, 2006, 335-344 |
||||
, Book chapter | ||||
, Germany | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2006 | German | ||
Quantifying the impact of fear of hypoglycaemia on quality of life | ||||
Walters N, Gordois A, Brown A, Lindsay P, Gonzalo F, Comas S | ||||
ISPOR 9th Annual European Congress |
||||
, Poster | ||||
, Australia | ||||
Condition | Year | Language | Analysis type | |
, Diabetes, Health economics | 2006 | English | , Burden of illness | |
When Direct-to-Patient health and prescription drug information is already a reality through the Internet. | ||||
Badia X, Alonso-Rodríguez Piedra N | ||||
Rev Esp Econ Salud 2006;5(5):272-5 |
||||
, Article | ||||
, Spain | ||||
Condition | Year | Language | Analysis type | |
, Health economics | 2006 | Spanish | ||
A multi-country economic evaluation of low-dose aspirin in the primary prevention of cardiovascular disease. | ||||
Lamotte M, Annemans L, Evers T, Kubin M | ||||
Pharmacoeconomics, 2006, 24(2): 155-169 Pharmacoeconomics; 24:155-69 |
||||
, Article, Manuscript in preparation | ||||
, Belgium | ||||
Condition | Year | Language | Analysis type | |
, Cardiovascular disease, Health economics | 2006 | English | , Economic evaluation | |
Economic evaluation of surgical treatment vs. Imiquimod 5% cream in patients with Superficial Basal Cell Carcinoma | ||||
Vanaclocha F, Badia X, Guillén V, Sánchez J, Sáinz de los Terreros M, Llorens MA. | ||||
Br J Dermatol. 2007 Apr;156(4):769-71. |
||||
, Article | ||||
, Spain | ||||
Abstract: http://www3.interscience.wiley.com/journal/117983521/abstract?CRETRY=1&SRETRY=0 | ||||
Condition | Year | Language | Analysis type | |
, Health economics, Oncology | 2006 | English | ||